Handbook here.

ok bo nd Ha

Harrogate International Centre 23–26 May

focusonchange

Innovation is in our

NA

Innovative Science to improve the patient experience and reduce the cost of care. Beckman Coulter is one of the leading providers of in vitro diagnostic systems to hospital laboratories throughout the world. We are uniquely positioned as a company with both research and diagnostic divisions to lead the way in biomedical testing. Our focus in Harrogate will be to share with you some of our innovative science and demonstrate how this innovation can improve the patient experience and reduce the cost of healthcare Please join us on stand 18 to experience our technology briefings on Novel Markers or attend our Industry Sponsored Workshop on:

Thursday 26th May

10.45 – 11.45

Prostate Health Index (phi) – Challenges to the early detection of prostate cancer and the impact of a new biomarker

Email: [email protected]

www.beckmancoulter.co.uk

Introduction

Acknowledgements President’s Message Chairman’s Message General Information Conference Centre Layout Map of Harrogate Welcome to Harrogate

Contents

Contents

2 4 6 8 12 13 14

Scientific Programme Programme Summary Speaker Profiles Monday - Training Day Tuesday Wednesday Thursday snippets@Focus

17 19, 23, 27 18 20 24 28 29

Satellite Meeting

National Point of Care Co-ordinators Meeting

Posters

22

ACB Poster Prizes Tuesday Wednesday Thursday

33 34 38 41

Floorplan Index of Participating Companies Abstracts of Participating Companies

46 47 48

Exhibition

Our Thanks to

Inside Back Cover

1

Focus 2011 | Introduc8on | Acknowledgements

2

Acknowledgements

Focus 2011 was organised by the Local Organising Committee under the guidelines provided by the Council of the Association for Clinical Biochemistry.

Focus 2011 Local Organising Committee Steve Goodall Eric Kilpatrick Gwyn McCreanor Sally Slack David Horne Mark Weaver

Chair Scientific Programme Chair Treasurer Social Events & Publicity Corporate Members’ Representative Corporate Members’ Representative

Scientific Programme Committee Eric Kilpatrick Chair Ian Barlow Ashley Garner Brian Keevil Stuart Smellie

With the assistance of

Vicki Grant, Stephanie Mair, Colette Craig, Meeting Makers Heidi Cox, Social Events & Publicity Ian Hanning, ACB National Meetings Secretary Kathryn Brownbill, ACB National Meetings Committee Ian Godber, ACB National Meetings Committee Charles van Heyningen, Editor, Proceedings of the ACB National Meeting Jonathan Berg, Editor, ACB News Nic Law and the ACB Office Staff ACB Executive Committee The Local Organising Committee also wishes to acknowledge the help of: Nikki Beeson, John Williams, Sue Ojakowa and the staff at the Harrogate International Centre

ISSN No 0959-860X Designed by John Williams and Nikki Beeson Printed by Swan Print Ltd, Bedford Published by PRC Associates Ltd on behalf of the Association for Clinical Biochemistry Edited by Ian Hanning of ACB News Photography supplied by Jonathan Berg

Focus 2011 | Introduc8on | Welcome

4

A message from

Julian Barth

President of the Association for Clinical Biochemistry

On behalf of the Association for Clinical Biochemistry, I’m delighted to welcome delegates to Harrogate and to Focus 2011. This is the first time that Focus has been held in Harrogate and, indeed, Yorkshire.

The theme for this year’s meeting is “Focus on Change” and this is reflected in the scientific programme and the changes in the meeting format. As scientists we are used to change. It is always expected and has become routine in our profession. We do not always want change, though, and new ideas presented in the literature and at scientific meetings frequently divide the scientific community in their opinions. This, in my view, leads to healthy debate, and in itself produces even more new ideas. We anticipate with relish the debates in the programme. This year, speakers will undoubtedly challenge commonly held beliefs and will provide delegates with many ideas to help guide them through the optimal paths for laboratory improvement, provision of services and improvements in the way patients are diagnosed and treated. The new “Hot Topics” plenary session has been carefully chosen to stimulate lively discussion. The whole programme is exciting and varied and should cater for all tastes. The variability keeps the programme fresh and also reminds us that the Association continues to welcome scientists from a broad spectrum of laboratory specialties as its members. The format of the meeting has also changed. We welcome the novel “All Day Breakfast” workshops, changes in the naming and timing of the Award Lectures and the increased involvement of the Corporate Members in their sponsorship of the scientific sessions. Positive feedback from previous years’ meetings has guided us to keep the “old favourites” in the programme: Attended Poster, Clinical Cases, Audit and Industry Sponsored Workshop sessions.

Every year, we expect our profession to face new financial challenges. This year is no exception. Not all talks are focussed on finance, but many will contain information on how savings can be made. The problems facing us in the UK are frequently encountered in other countries. We welcome our colleagues from outside the UK and look forward to the interchange of ideas from the wider scientific community.

Yorkshire people are well known for speaking their mind, just as we scientists do. They are also well known for their welcome and hospitality, just like the ACB. We hope you enjoy your stay in Harrogate, and the pleasures and new knowledge that Focus 2011 will provide.

Focus 2011 | Introduc8on | Welcome

6

A message from

Steve Goodall

Chairman of the Local Organising Committee

I am delighted to invite the scientific community to join us in Harrogate for Focus 2011. This is the first time that Focus has been held in Yorkshire, so delegates will be able to look forward to some brand new experiences. Yorkshire folk are renowned for having short arms and long pockets, but do not expect to be short-changed at Focus. Harrogate, and Focus 2011, have much to offer, from Bettys Café to cutting-edge scientific advances.

The strapline – Focus on Change – is more apt than ever before, particularly for UK delegates, as we anticipate major changes in the way we deliver pathology services. This does not mean that the whole meeting is directed towards this topic. Professor Eric Kilpatrick and the Scientific Programme Committee have created a very exciting and wide-ranging programme that addresses changes not only in service provision, but also in scientific knowledge and application.

The idea of a new style Focus has been discussed for many years, and the Focus format has changed with the times. Focus 2011 will see a move away from a large commercial exhibition, and will see Corporate Members becoming more involved in sponsoring and supporting the scientific programme. This is a new development that was requested by the companies and the Local Organising Committee is delighted to be able to incorporate the new ideas. Change indeed.

I cannot remember a time when pathology services ever stood still. New assays, technologies and methodologies; phone calls from clinicians wanting to discuss interesting patients; new knowledge in our understanding of disease processes and treatment of patients; the way we train our juniors. We live in a world with changing scenery and this, to me, is what makes our jobs so varied, interesting and rewarding. It is also what contributes to improving patient care.

Yorkshire is a varied county. It has spectacular scenery: wild moors, rugged coastline, holiday resorts, large centres of law, arts and academia. Yorkshire even has its own tongue-in-cheek song about cannibalism on Ilkla’ (Ilkley) Moor. There are wonderful museums and places to visit. Something for everyone, just like Focus 2011. So we look forward to welcoming you to Harrogate, and we predict you will have a hugely enjoyable and informative meeting.

Focus 2011 | Introduc8on | General informa8on

8

General information Venue

The venue for Focus 2011 is the Harrogate Interna8onal Centre (HIC), King’s Road, Harrogate, North Yorkshire HG1 5LA.

Tel: 01423 500 500 Website: www.harrogateinterna0onalcentre.co.uk

Tourist Information

Harrogate Tourist Informa8on Centre:

Tel: 01423 537303 Email: [email protected] Website: www.harrogate.gov.uk/immediacy-4660

Getting to the Venue

Harrogate is ideally situated in the middle of the UK, equidistant from both London and Edinburgh. It has good train links, is easily accessible by car via the M1 and is only 20 minutes away from Leeds Bradford airport. For detailed informa8on on travel to the venue please visit the Harrogate Interna8onal Centre website: www.harrogateinterna8onalcentre.co.uk/About-Us/Ge:ng-Here.aspx

To get from the airport to Harrogate, the Dales and District 767 bus will drop you off at the bus sta8on, then it is just a short walk to the Harrogate Interna8onal Centre.

The closest bus stop to the Harrogate Interna8onal Centre is Cheltenham Crescent. More informa8on can be found at: www.dalesanddistrict.co.uk or Tel: 01677 425203. Harrogate Interna8onal Centre is easily accessible by train. When at Leeds/York there is a simple change to a Harrogate bound train. These run every half hour (through the week) with an average journey 8me of 30-40 mins.

For more informa8on on trains to and from Harrogate please call Na8onal Rail Enquiries Tel: 08457 48 49 50 or www.na8onalrail.co.uk Driving to Harrogate Interna8onal Centre: There are 210 car parking spaces at the Harrogate Interna8onal Centre, with a further 1,200 at the nearby Jubilee and Victoria car parks.

Monday registra8on will take place in the King’s Suite Entrance. For the remainder of the week, the Registra8on Desk will be located in the main recep8on of the Harrogate Interna8onal Centre and will be open from: 08.00-18.00 on Monday 23rd May, 08.00-17.00 on Tuesday 24th and Wednesday 25th May, and from 08.15-16.00 on Thursday 26th May.

Hotels

For loca8ons, see map on page 13.

Any queries regarding accommoda0on bookings made through Focus 2011 Secretariat should be addressed directly to Mee0ng Makers. At the 8me of booking all delegates were required to provide credit card details to secure their booking. These details have been forwarded to the hotel, but payment will not have been taken. Delegates must se9le their own accounts on departure from their hotel. In the event of a cancella8on of a hotel booking received a(er the 25th March, the hotel will deduct from your credit card an amount equal to the dura8on of the stay booked. Resident delegates must comply with the check-out 8mes of individual hotels and ensure that all charges are cleared before departure. Those needing to leave luggage on the first or last day can do so at the main cloakroom of the Harrogate Interna8onal Centre.

Hotel Contact Details Holiday Inn

Kings Road, Harrogate HG1 XX Tel: 01423 849 988

Hotel du Vin

Prospect Place, Harrogate HG1 1XX Tel: 01423 856 800

Majestic Hotel

Ripon Road, Harrogate HG1 2HU Tel: 01423 700 300

Old Swan

Swan Road, Harrogate HG1 2SR Tel: 01423 500055

Conference Information

Any urgent messages received for delegates will be displayed on a no8ce board in the registra8on area at Harrogate Interna8onal Centre.

Scientific Sessions

Please refer to the programme on pages 17-28 for full details.

Focus 2011 | Introduc8on | General informa8on

Arrival/Registration

All Day Breakfast Workshops

These will take place in the Queen’s Suite of the Harrogate Interna8onal Centre from 08.45-16.40 on Tuesday 24th May and 08.45-15.55 on Wednesday 25th May.

Posters

Posters will be displayed in the Exhibi8on Hall. Presen8ng authors are required to be present from 13.00-13.45. Posters should be mounted between 08.00-09.00 and removed by the following 8mes to prevent disposal: Tuesday - 17.00 Wednesday - 17.00 Thursday - 14.00

9

Focus 2011 | Introduc8on | General informa8on

10

Annual General Meetings

These will be held on Monday 23rd May and will be preceded by an informal drinks recep8on which will take place in the King’s Suite from 16.30-17.15 before the mee8ngs commence.

The AGM of the Federa8on of Clinical Scien8sts will be from 17.15-17.45, followed by the AGM of the Associa8on for Clinical Biochemistry from 18.00-18.45.

Exhibition

The Focus Exhibi8on opening 8mes are as follows: Tuesday 24th May Wednesday 25th May Thursday 26th May

10.00-19.00 10.00-17.30 10.00-14.30

WiFi Access

The Harrogate Interna8onal Centre has WiFi access available. There is a charge for this service and delegates are required to purchase vouchers from the Harrogate Interna8onal Centre Main recep8on desk or the Hall Q support office. The cost is £4.00 for 60 minutes.

Catering

Refreshments and lunch will be provided at the catering points in the Exhibi8on Hall, Hall Q. Coffee and Tea will be provided from 10.45-11.45 and 14.00-15.15 on Tuesday and Wednesday and from 10.45-11.45 on Thursday. Lunch will be provided from 12.30-14.00 on Tuesday, Wednesday and Thursday.

At present there are no public telephones in The Harrogate Interna8onal Centre. The nearest public telephone is in the Holiday Inn Hotel.

Cloakroom

Cloakrooms are available in the entrance of the Harrogate Interna8onal Centre.

Cashpoint

The nearest cashpoint is in the Harrogate Interna8onal Centre outside Hall M - there is no charge for using this machine for withdrawing cash. If for some reason it is unavailable then there are cashpoints on Parliament Street and outside all the major banks.

Security

Delegates are reminded to wear their Focus badges at all 8mes. Entry to the Scien8fic Symposia will be restricted to persons wearing appropriate badges. Those wearing

Exhibi8on Visitor badges will only be allowed into the Focus Exhibi8on.

Mobile Phones and Pagers

As a courtesy to speakers and other delegates, mobile phones and pagers must be switched off, or set to a non-audible alert, before entering lecture theatres or mee8ng room.

Audio Visual Service

Focus 2011 | Introduc8on | General informa8on

Public Telephones

The speakers’ preview room will be in the main recep8on area behind the Registra8on Desk. Please ask registra8on staff for guidance on accessing the area.

CPD

The mee8ng is registered for CPD with the Royal College of Pathologists and the Ins8tute of Biomedical Science. Cer8ficates of A9endance can be collected from the Registra8on Desk.

Delegates are reminded to sign in each morning. Sign in sheets will be located in the registra8on area.

Smoking

Focus 2011 is a non-smoking event.

11

Focus 2011 | Introduc8on | Maps and Plans 12

Conference Centre Layout

13

Focus 2011 | Introduc8on | Maps and Plans

Focus 2011 | Introduc8on | Welcome to Harrogate

14

Welcome to Harrogate Deliciously Yorkshire . . .

This charming town on the edge of the Yorkshire Dales boasts characteristic architecture, grand boulevards, café-lined streets, elegant boutiques and flower-filled green spaces. Harrogate is Britain’s original spa town. The town’s first well was discovered in 1571 by William Slingsby who christened the town “The English Spa”.

Famous for its sulphur and iron rich waters, Harrogate water gained popularity when an 18th century physician called Timothy Bight claimed that the spa water had healing properties. It was claimed that the waters of Harrogate could cure gout, rheumatism and nervous tension. Although the healing properties of Harrogate water have never been proven in randomised controlled trials, over 50,000,000 bottles of Harrogate Spring Water are sold throughout Britain every year!

Nowhere serves a cup of tea like Bettys Tea Rooms of Harrogate. Established in 1919 it is still serving the finest cuppa with delicious Yorkshire and continental confections. Bettys is nestled amongst Harrogate’s famous 19th century Turkish Baths, unique shops and over 100 cosmopolitan restaurants and bars. All just a few minutes walk away from your conference centre and accommodation. For those of you choosing to stay and explore Harrogate before or after the conference you are not short of options:

• Browse antiques and unusual gifts in the stylish Montpellier Quarter.

• De-stress and relax in the steam and

hot rooms of the preserved Turkish Spa Baths, built in 1897 and restored in 2004.

• Enjoy a stroll around the town, admiring its award winning floral displays en route. The town boasts 200 acres of green lawns which surround the town.

Society Gardens at Harlow Carr.

• Put on your hiking boots and explore.

Walking in this area of North Yorkshire is fantastic. Brimham Rocks are an amazing collection of weird and wonderful rock formations, whilst Malham Cove is a unique natural amphitheatre made up of curved limestone cliffs. Both definitely worth a visit with your cameras at the ready.

• Visit the nearby Black Sheep Brewery for a tour. In a world of ever increasing bland, mass-produced beer these boys are serious about their traditional ale!

You are not short of options when looking to explore this region. As a local once said “If it’s artside Yorkshire, it int w’th bl*ddy visitin!”. We hope you enjoy all that this fantastic area has to offer.

It’s not so grim up north after all!

Focus 2011 | Introduc8on | Welcome to Harrogate

• Visit the impressive Royal Horticultural

15

Monday 23rd May

09.30-16.30 17.15-17.45 18.00-18.45

Training Day AGM of the Federation of Clinical Scientists AGM of the Association for Clinical Biochemistry

08.45-10.45

Parallel Sessions: New Technologies Point of Care Testing EBLM Workshop Break and Industry Sponsored Workshops ACB Foundation Award Lecture Lunch and Exhibition Attended Poster Session RCPath Flynn Lecture Break Parallel Sessions: Blood Sciences Laboratory Audit The Novel Application of POC Diagnostics

Tuesday 24th May 08.45-11.15 10.45-11.45 11.45-12.30 12.30-14.00 13.00-13.45 14.00-14.45 14.45-15.15 15.15-17.15

Wednesday 25th May 08.45-10.45

10.45-11.45 11.45-12.30 12.30-14.00 13.00-13.45 14.00-14.45 14.45-15.15 15.15-17.15

Focus 2011 | Programme | Summary

Summary Programme

Parallel Sessions: Clinical Chemistry and the Coroner Cancer: Meeting the Needs of the Patient Break and Industry Sponsored Workshops ACB International Lecture Lunch and Exhibition Attended Poster Session and Hot Topic Posters Professors’ Prize Lecture Break Parallel Sessions: Clinical Practice Section Research in Clinical Biochemistry ACB Medal Awards

Thursday 26th May 08.45-10.45

10.45-11.45 11.45-12.30 12.30-14.00 13.00-13.45 14.00-16.00 16.00

Parallel Sessions: Clinical Cases Clinical Chemistry in the Age of Austerity Break and Industry Sponsored Workshops AACC Transatlantic Award Lecture Lunch and Exhibition Attended Poster Session Hot Topics Closing Remarks and Presentation of Awards 17

Focus 2011 | Programme | Sunday & Monday

18

Sunday 22nd May 19.30-22.30

Trainees’ Dinner

RESTAURANT BAR & GRILL

Trainees are invited to join members of the Education Committee and Training Day speakers for dinner at the Restaurant Bar & Grill, 46-48 Parliament Street, Harrogate HG1 2RL.

Monday 23rd May Training Day 09.30-12.30

12.30-13.30 13.30-16.30

Clinical Cases

KING’S SUITE

Lunch

KING’S SUITE

Led by Dr Danielle Freedman Dr Freedman will be bringing her clinical knowledge and experience to this interactive session on clinical cases. This session will be useful for Trainees preparing for their FRCPath exams.

Transforming Pathology Services

KING’S SUITE

Led by Alan Thorne The NHS is facing a challenging future with an increasing demand for services but with limited resources. Alan Thorne will bring his experience of change management and staff engagement to the session on Transforming Pathology.

16.30-18.45

Reception and Annual General Meetings

18.00-18.45

17.15-17.45

AGM of the Federation of Clinical Scientists AGM of the Association for Clinical Biochemistry

19.30-late

Corporate Members’ Evening

An informal drinks reception will precede the AGMs.

KING’S SUITE

THE ROYAL HALL

The Corporate Members' Evening will be held in The Royal Hall, a stunning Edwardian Theatre built in 1903. Restored to its original magnificence in 2008, this ‘palace of glittering gold’ has to be the ultimate backdrop for a memorable evening. The Royal Hall is situated within the conference centre and is a short walk from your conference hotel.

Dr Ian Watson

Ian Watson is Clinical Director and Consultant Clinical Biochemist and Toxicologist at University Hospital Aintree, Liverpool, with specialist clinical interests in Analytical Toxicology, Neurobiochemistry, and POCT. He is President of the European Federation of Clinical Chemistry and Laboratory Medicine, a Past-President of the Association for Clinical Biochemistry and of the International Association for Therapeutic Drug Monitoring and Clinical Toxicology.

Toxicology has had a very different spectrum of analytical and clinical challenges over 40 years ago and having been a part of some of the action over this time he has published over 100 peer-reviewed publications, 3 books and several book chapters, mainly on toxicology-related topics.

He is Chair of the Heathcontrol EQA Scheme for Drug Assays; has led in the production of UK National Guidelines on the Laboratory and Poisoning, and in their current revision. He has also helped develop national guidance on the laboratory detection of intra-cranial bleed and adoption of HbA1c standardisation. He remains an active drummer!

Dr Danielle Freedman

Danielle Freedman MB BS, FRCPath, EurClinChem is a Consultant Chemical Pathologist and Associate Physician in Clinical Endocrinology, Clinical Director for Pathology and Anticoagulation, Luton and Dunstable NHS Foundation Trust. In addition, she was the Hospital Medical Director from October 2005 until December 2010.

Focus 2011 | Speaker Profiles | Tuesday

Plenary Speaker Profiles – Tuesday

She trained in Medicine at the Royal Free Hospital School of Medicine, London University and undertook further training in Clinical Biochemistry and Endocrinology both at the Royal Free Hospital and the Middlesex Hospital, London.

Nationally, she is an elected Vice President of the Royal College of Pathologists (RCPath) and sits on the RCPath Executive and Council. She is Chair of the RCPath Speciality Advisory Committee for Clinical Biochemistry and is a Member of the Department of Health National Pathology Futures Group and Pathology Messaging and Interoperability Board. She is a CPA National Assessor and Member of the UK NEQAS Clinical Chemistry Advisory Group for Interpretative Comments. Her main interests include clinical endocrinology, point of care testing and, importantly, the role of the laboratory/clinician interface with regard to patient safety and patient outcome.

She has over 100 publications in peer review journals including Lancet, New England Journal of Medicine, JAMA and Annals of Clinical Biochemistry in her areas of interest. She is a frequently invited speaker both nationally and internationally on the above topics. She won the ‘Outstanding Speaker’ Award in 2009 from the American Association of Clinical Chemistry (AACC) and is a Member of the AACC Annual Meeting Organising Committee for 2011.

19

Focus 2011 | Programme | Tuesday

20

Tuesday 24th May 08.45-10.45

Parallel Sessions

New Technologies

Point of Care Testing

Chair: Mr Brian Keevil, Manchester

Chair: Mr Ian Barlow, Scunthorpe

HALL D

08.45-09.15 The use of accurate mass in LC/MS determinations Dr Mike Morris, Manchester

09.15-09.45 Engineering femtomolar affinity antibodies for improved assay sensitivity Dr Dagang Huang, Illinois, USA 09.45-10.15 Nanoscale diagnostics: probing protein structure and function at the single molecule level Prof John Ryan, Oxford 10.15-10.45 Future directions for biosensors Prof John Pickup, London

08.45-11.15

MAIN AUDITORIUM

08.45-09.15 UKAS accreditation for point of care testing Dr Jane Beaumont, London

09.15-09.45 Straight to the point: iPOCT first to gain UK accreditation for point of care testing Ms Claire Pridige, Skipton

09.45-10.15 Blunders and how to avoid them Mrs Lynda Petley, Frimley Park

10.15-10.45 Point of care testing in the development of primary care Prof Chris Price, Oxford Sponsored by

Diagnostics

EBLM Workshop

KING’S SUITE

Enhance your EBLM skills at this workshop organised by the ACB Education and Scientific Committees. The workshop aims to help participants develop EBLM skills and will include the following sessions: Formulating the Question Acquiring the Evidence Appraising the Evidence

Working in groups, under the guidance of a mentor, a number of topical issues will be covered.

10.45-11.45

Break and Industry Sponsored Workshops Ortho Clinical Diagnostics Waters Advances in Clinical and Blood Sciences Laboratory in Forensic Mass Spectrometry the Small or Specialist Hospital: Is it a Worthwhile Approach? QUEEN’S SUITE 6 QUEEN’S SUITE 2

Chair: Peter Clements, Ortho Clinical Diagnostics

David Wells, Great Ormond Street Hospital

The principle of a Blood Sciences Laboratory in the large high throughput routine laboratory is an accepted model for producing efficiencies and financial benefits. Applying this approach on a smaller scale to mainstream testing at Great Ormond Street Hospital has delivered unique benefits for the provision of specialist testing services; justifying the project costs.

Chair: tbc

Use of the novel acquisition mode MSe for comprehensive toxicological screening Dr Mike Morris, Manchester

Followed by Waters latest technology update.

12.30-14.00 13.00-13.45 14.00-14.45

14.45-15.15 15.15-17.15

ACB Foundation Award Lecture Illuminating facets of analytical toxicology: past, present and future Dr Ian Watson, Aintree

HALL Q

Attended Poster Session

HALL Q

Flynn Lecture

MAIN AUDITORIUM

Chair: Dr Tim Wreghitt, Cambridge

POCT: dangerous indulgence or essential to quality care? Dr Danielle Freedman, Luton

Break

Parallel Sessions Blood Sciences Laboratory

Chair: Mr Ian Hanning, Hull

15.15-15.45 Haematinics in the Blood Sciences laboratory Dr Mike Galloway, Sunderland

15.45-16.15 Immunology in the Blood Sciences laboratory Dr Jo Sheldon, London

16.15-16.35 Microbiology in the Blood Sciences laboratory Dr Kate Templeton, Edinburgh

16.35-17.15 The Blood Sciences laboratory: the agony and the ecstasy Dr Jean Wardell, Doncaster and Dr Eileen Marks, Liverpool

Diagnostics

Sponsored by

All Day Breakfast Sessions

4: 15.15-15.55 5: 16.00-16.40

Diagnostics

Sponsored by

Lunch and Exhibition

MAIN AUDITORIUM

1: 08.45-09.25 2: 09.30-10.10 3: 10.15-10.55

MAIN AUDITORIUM

Chair: Dr Julian Barth, Leeds

HALL Q

Audit

QUEEN’S SUITE 2

Chair: Mrs Annette Thomas, Cardiff

15.15-15.55 National Audits Audit of internal quality control prac8ce and processes Dr David Housley, Luton Ms Teresa Teale, Winchester

Presenta0ons selected from submi1ed abstracts 15.55-16.15 Dr Afaf Hassan, Manchester (see poster T68) 16.15-16.35 Mr Edward Hinchliffe, Manchester (see poster 8) 16.35-16.55 Dr Lucy Hawkins, Tunbridge Wells (see poster T69) 16.55-17.15 Ms Ayesha Azam, Dudley (see poster 9)

The Novel Application of POC Diagnostics HALL D

Chair: tbc

15.15-15.55 A fully integrated approach to point of care testing Dr Devi Nair, London

15.55-16.35 Home monitoring of heart failure Prof Henry Dargie, Glasgow

16.35-16.45 Chest pain assessment using a panel of POC biomarkers Dr Sanjay Ramamoorthy, Southampton Hosted by

QUEEN’S SUITE

Trial statistics for dummies Dr Rick Jones, Leeds Urinary C-peptide for diagnosing MODY Mr Tim McDonald, Exeter Introducing new analysers or techniques into the medical laboratory: A practical guide to acceptance testing Dr Robert Hill, Sheffield HbA1c: two years on from standardisation Prof Eric Kilpatrick, Hull Pharmacogenomics of chemotherapy susceptibility Prof Ian Cree, Portsmouth

17.15-19.00

Reception in the Exhibition

21.00-late

Focus Fringe

Focus 2011 | Programme | Tuesday

11.45-12.30

There will be an extended drinks reception and buffet in the exhibition area immediately after the end of the day’s scientific programme giving delegates the opportunity to engage with our corporate members and network with colleagues in a relaxed atmosphere. Join us at Montey’s Rock Café, 3 The Ginnel, Harrogate HG1 2RB.

SUITE 4 SUITE 8 SUITE 4 SUITE 8 SUITE 4 HALL Q

MONTEY’S ROCK CAFÉ

21

Focus 2011 | Satellite Mee8ng | Tuesday

22

Tuesday 24th May Satellite Meeting

National Point of Care Testing Co-ordinators Meeting 08.45-10.45

Point of Care Testing*

Chair: Mr Ian Barlow, Scunthorpe

MAIN AUDITORIUM

08.45-09.15 UKAS accreditation for point of care testing Dr Jane Beaumont, London

09.15-09.45 Straight to the point: iPOCT first to gain UK accreditation for point of care testing Ms Claire Pridige, Skipton

09.45-10.15 Blunders and how to avoid them Mrs Lynda Petley, Frimley Park

11.45-12.30

12.30-14.00 14.00-14.45

15.15-17.15

10.15-10.45 Point of care testing in the development of primary care Prof Chris Price, Oxford

Morning Session

The role of the portable blood gas analyser in the community Mrs Sandra Hoyle, Manchester

Lunch & Exhibition Flynn Lecture*

Chair: Dr Tim Wreghitt, Cambridge

Sponsored by

Diagnostics

QUEEN’S SUITE 1

HALLS 1 & 2 MAIN AUDITORIUM

POCT: dangerous indulgence or essential to quality care? Dr Danielle Freedman, Luton

The Novel Application of POC Diagnostics*

HALL D

Chair: tbc

15.15-15.55 A fully integrated approach to point of care testing Dr Devi Nair, London 15.55-16.35 Home monitoring of heart failure Prof Henry Dargie, Glasgow

16.35-16.45 Chest pain assessment using a panel of POC biomarkers Dr Sanjay Ramamoorthy, Southampton

*ACB sessions

Hosted by

Prof Mario Plebani

Mario Plebani obtained his medical degree summa cum laude from the Medical School of University of Padova in 1975. He completed specialisa8on in Laboratory Medicine (1978), then Gastroenterology (1983), at the same University. In 1991 he was appointed Head of the Clinical Laboratory of the University-Hospital in Padova and in 2001 Chair of the Department of Laboratory Medicine. In 2003 he was appointed Full Professor of Clinical Chemistry and Clinical Molecular Biology at the Medical School.

Currently, he is Director of the Postgraduate School in Clinical Biochemistry and President of the course for Medical Technologists. He is a Fellow of RCPath and a Member of the ACB. He is Past-President of the Interna8onal Society of Enzymology (ISE) and of the Italian Society of Clinical Biochemistry and Molecular Clinical Biology. He is President of the Italian Federa8on of Scien8fic Socie8es of Laboratory Medicine (FISMeLAB).

He has published 700 original papers and is a recipient of a number of na8onal and interna8onal Awards, including the 2008 AACC Award for Outstanding Clinical Laboratory Contribu8ons to Pa8ent Safety. He is Editor in Chief of Clinical Chemistry and Laboratory Medicine (CCLM), and Associate Editor of other journals.

Dr Rossa Chiu

A(er gradua8ng from the University of Queensland, Australia, in 1997 with First Class Honours in Bachelor of Medicine and Bachelor of Surgery, Dr Rossa Chiu specialised in Chemical Pathology. She received postgraduate training in research and was awarded Doctor of Philosophy by The Chinese University of Hong Kong in 2004.

Focus 2011 | Speaker Profile | Wednesday

Plenary Speaker Profile – Wednesday

Dr Chiu joined the Department of Chemical Pathology, The Chinese University of Hong Kong in 1999 as Assistant Professor, became Associate Professor in 2004 and then Senior Lecturer, her current posi8on, in 2008. She is also an Honorary Consultant at the New Territories East Cluster of Hospitals, Hong Kong.

Dr Chiu’s main research interests include the development of non-invasive prenatal diagnos8c approaches, novel molecular diagnos8c strategies and innova8ve applica8ons of molecular analysis tools. She was the first to develop approaches to apply cell-free fetal DNA analysis in maternal plasma for the non-invasive prenatal diagnosis of autosomal recessive diseases. Recently, she was the first to perform a large scale study to demonstrate the effec8veness of massively parallel sequencing as a clinical diagnos8c tool for non-invasive prenatal diagnosis of Down’s syndrome.

To date, Dr Chiu has published over 100 peer-reviewed research ar8cles, 15 books or monographs, delivered over 30 invited presenta8ons and has 19 granted patents or patent applica8ons. Dr Chiu has been awarded the IFCC Roche Young Inves8gator Award in 2011, plus other awards. She is Past President of the Hong Kong Society of Clinical Chemistry.

23

Focus 2011 | Programme | Wednesday

24

Wednesday 25th May 08.45-10.45

Parallel Sessions

Clinical Chemistry and the Coroner

Cancer: Meeting the Needs of the Patient

Chair: Dr Ian Watson, Aintree

Chair: Dr Margaret McDonnell, Belfast

MAIN AUDITORIUM

HALL D

08.45-09.15 Forensic work: legal aspects/required standards and the implications for NHS Clinical Chemistry laboratories Mr Andrew Rennison, Birmingham

08.45-09.15 Cancer in the UK Ms Louise Jones, Cancer Research UK

09.45-10.15 Forensic/Morbid cases Dr Nigel Cooper, Newcastle

09.45-10.15 Ovarian cancer Prof Ian Jacobs, London

09.15-09.45 The laboratory investigation of forensic toxicology cases Dr Stephen George, Birmingham

10.15-10.45 Coronial work: future developments Dr Stephen Morley, Sheffield

09.15-09.45 The laboratory and cancer: the role of biomarkers in the diagnosis, monitoring and treatment of cancer Dr Cathie Sturgeon, Edinburgh

10.15-10.45 Lung cancer Dr Petra Stieber, Munich, Germany Hosted by

10.45-11.45

Break and Industry Sponsored Workshops

QUEEN’S SUITE

Immunodiagnostic Systems (IDS) Ltd Clinical Application of Bone Markers

Sebia UK Ltd

Chair: Dr Richard Eastell, Sheffield

Myeloma, The Patient’s Perspective

QUEEN’S SUITE 2

Prof Erik Fink Eriksen, Oslo

QUEEN’S SUITE 6 Chair: tbc

Mr Eric Low, Chief Executive, Myeloma UK

New Applications for the Sebia Capillarys2 Flex Piercing Mr Martin Hurl, Sebia UK Ltd

11.45-12.30

12.30-14.00 13.00-13.45

ACB International Lecture Chair: Dr Julian Barth, Leeds

MAIN AUDITORIUM

An unfinished journey: the role of laboratory medicine in patient safety Prof Mario Plebani, Padova, Italy

Lunch and Exhibition

Attended Poster Session and Hot Topic Posters

HALL Q HALL Q

14.45-15.15 15.15-17.15

Professors’ Prize Lecture

MAIN AUDITORIUM

Chair: Prof Gordon Ferns, Keele

Non-invasive prenatal diagnosis empowered by massively parallel sequencing Dr Rossa Chiu, Hong Kong

Break

Parallel Sessions

HALL Q

Clinical Practice Section

Research in Clinical Biochemistry

Chair: Dr Stuart Smellie, Bishop Auckland

Chair: Dr Ashley Garner, Leeds

HALL D

15.15-16.15 Head over the parapet: suggestions for harmonising laboratory profile content Dr Stuart Smellie, Bishop Auckland

16.15-17.15 The Great Debate: Genetic screening for familial hypercholesterolaemia is a priority For:

Dr Dermot Neely, Newcastle-upon-Tyne

Against: Prof Jonathan Kay, Oxford

MAIN AUDITORIUM

15.15-15.45 Current research activity in clinical biochemistry laboratories: what does the future hold for biomarker research programmes? Miss Sophie Hepburn, Leeds 15.45-16.15 Funding opportunities for clinical biochemistry research Prof Lindsay Turnbull, Hull

16.15-16.45 Turning ideas into funded research Prof Ian Young, Belfast 16.45-17.15 Doing meaningful research with limited resource Prof Eric Kilpatrick, Hull

Focus 2011 | Programme | Wednesday

14.00-14.45

25

Focus 2011 | Programme | Wednesday

26

15.15-17.15

ACB Medal Awards

Chair: Dr Julian Barth, President, Association for Clinical Biochemistry

QUEEN’S SUITE 2

15.15-15.35 Evaluation of a kisspeptin assay as a screening tool for pre-eclampsia James Logie, Wishaw 15.35-15.55 Glycosylation of IgG paraproteins: a potential marker of malignancy Jessica Schroeder, Redditch

15.55-16.15 Single nucleotide polymorphisms in the tyrosinase gene and their association with the risk of and severity of multiple sclerosis Naomi Rankin, Stoke-on-Trent 16.15-16.35 Development of an assay for the genetic diagnosis of 17β-hydroxysteroid dehydrogenase type 3 deficiency Ghazaleh Esmaeil Pourmahram, Hertfordshire

16.35-16.55 Real-time PCR genotyping of four SNPs associated with warfarin sensitivity and their frequency in an anticoagulated patient group Fiona Davidson, Bristol

16.55-17.15 Manipulation of the active site of human glycolate oxidase to assess the role of long-chain hydroxy-acid oxidase in glyoxylate metabolism Nick Unsworth, London

Sponsored by

All Day Breakfast Sessions

6: 7: 8: 9:

08.45-09.25 09.30-10.10 10.15-10.55 15.15-15.55

19.30-23.30

Hypoglycaemia Dr Tim Lang, Durham Treating diabetes in the 10s Dr Paul Peter, Bishop Auckland Complex dyslipidaemias Dr Tony Wierzbicki, London Adding value: a consultant resource pack Dr Mike Bosomworth, Leeds

Conference Dinner

QUEEN’S SUITE

SUITE 4 SUITE 8 SUITE 4 SUITE 8

THE ROYAL HALL

The conference dinner will be held in the Royal Hall which is part of the Harrogate International Centre Complex and is only a short walk from all the conference hotels. Pre-dinner drinks will be followed by dinner and entertainment. To acknowledge the fact that we are lucky enough to spend the evening in the Royal Hall in the year of the Royal Wedding, we invite you to dress for a Royal Party.

Prof Robin Felder

Professor Felder is Associate Director of Clinical Chemistry, the former Director of the Medical Automation Research Center, and a Professor of Pathology at the University of Virginia in Charlottesville, Virginia. His affiliation with professional organizations includes Past President and Founder of the Association for Laboratory Automation and Founding Editor of its journal, Fellow of the Council for High Blood Pressure Research (a council of the American Heart Association) and a Fellow of the National Association for Clinical Biochemists. He has published over 260 research papers, has been awarded 12 patents, and has presented over 140 lectures in 15 countries. He has received numerous awards including the International Engelberger Award for Robotics in 2009, the Research Awards from the American Association for Clinical Chemistry and the National Academy of Clinical Biochemistry in 2010, and one of his inventions was named a Top 10 Technology by The Scientist in 2009. In addition to his academic career, Professor Felder has co-founded 9 private ventures spun out from the University of Virginia, including www.medicalautomation.com, www.globalcellsolutions.com, www.hypogen.com, www.labautomation.org, www.medicalautomation.org, www.wellawaresystems.com, BioPhile Inc, Ibetics LLC, and Medical Robotics LLC.

Focus 2011 | Speaker Profile | Thursday

Plenary Speaker Profile – Thursday

27

Focus 2011 | Programme | Thursday

28

Thursday 26th May 08.45-10.45

Parallel Sessions Clinical Cases

MAIN AUDITORIUM

Chair: Dr Danielle Freedman, Luton

Cases by Dr Danielle Freedman, Luton Mr Mike Hallworth, Shrewsbury Prof Jonathan Kay, Oxford Prof Eric Kilpatrick, Hull Mrs Ruth Lapworth, Ashford

10.45-11.45

Clinical Chemistry in the Age of Austerity HALL D

Chair: Dr Martin Myers, Preston

08.45-09.25 Pathology transformation: the developing landscape Dr Ian Barnes, Leeds 09.25-10.05 Pathology re-engineering Mr Peter Wisher, Lincoln 10.05-10.45 Pathology: the organisational challenge Mr Phil Hudson, Manchester

Break and Industry Sponsored Workshops Alpha Laboratories Ltd Focus on AKI with NGAL & Liver Fibrosis with Hyaluronic Acid QUEEN’S SUITE 2

Chair: Dr Jean Wardell, Doncaster

The Use of HA in a Clinical Setting

Prof PC Hayes, Professor of Hepatology, Liver Unit, Royal Infirmary of Edinburgh

NGAL in Clinical Practice

Beckman Coulter UK Ltd Prostate Health Index QUEEN’S SUITE 6

Chair: Mark Stearman, Beckman Coulter UK Ltd

Challenges to the early detection of prostate cancer and the impact of a new biomarker

Dr Marlies Ostermann, Consultant Nephrologist, Guy’s Hospital, London

11.45-12.30

12.30-14.00 13.00-13.45 14.00-16.00

AACC Transatlantic Award Lecture Chair: Dr Mike Thomas, London

MAIN AUDITORIUM

Laboratory automation; the next generation Prof Robin Felder, Charlottesville, USA

Lunch and Exhibition

Attended Poster Session Hot Topics

Chair: Prof Eric Kilpatrick, Hull

HALL Q HALL Q MAIN AUDITORIUM

HbA1c for diabetes diagnosis: for better or for worse? Prof W Garry John, Norfolk & Norwich

Vitamin D Prof William Fraser, Norwich

16.00

High sensitivity troponins: how should we be using them? Dr Paul Collinson, London

Closing Remarks and Presentation of Awards

MAIN AUDITORIUM

Chair: Dr Julian Barth, President, Association for Clinical Biochemistry

snippets@Focus will give all delegates the opportunity to engage with a wide range of scientific, managerial and work-related topics. The snippets@Focus presentation area is located Hall Q. Sessions will take place each day during the breaks and are open to all. The day-to-day schedule is given below.

Tuesday 24th May 11.00-11.15

T1

11.25-11.40 12.40-12.55

T2 T3

13.05-13.20 13.30-13.45 14.55-15.10

T4 T5 T6

Automa0on of assays in the clinical laboratory using a GERSTEL mul0-purpose sampler (MPS) Cliquid™ and iMethods™ - LC-MS/MS solu0ons for clinical research Introduc0on to heavy-light chain (Hevylite) assays and their clinical applica0ons An introduc0on to the LIAISON XL® What is the future for HbA1c tes0ng? Analysis of Vitamin D metabolites by tandem mass spectrometry and online extrac0on

Wednesday 25th May 11.00-11.15 11.25-11.40

W1 W2

12.40-12.55 13.05-13.20 13.30-13.45

W3 W4 W5

What is the future for HbA1c tes0ng? Introduc0on to heavy-light chain (Hevylite) assays and their clinical applica0ons Hypogonadism, insulin resistance and cardiovascular risk A quick and easy ‘new genera0on’ test for colorectal cancer Liquid chromatograhy-tandem mass spectrometry solu0ons for steroid analysis

Focus 2011 | Exhibi8on | snippets@Focus

snippets@Focus

Thursday 26th May 11.25-11.40

Th2

12.40-12.55

Th3

13.30-13.45

Th5

Agilent Technologies Clinical Applica0ons Including 1,25-Dihydroxyvitamin D3 and D2 Introduc0on to heavy-light chain (Hevylite) assays and their clinical applica0ons Improving transparency and tracking of pathology samples and clinical trials

29

Focus 2011 | Exhibi8on | snippets@Focus

30

Tuesday 24th May 11.00-11.15

11.25-11.40

Anatune Ltd

T1: Automa0on of assays in the clinical laboratory using a GERSTEL mul0-purpose sampler (MPS) Bob Green Presented are two simple to operate automated assays. The analysis of Vitamin D in blood serum and the analysis of selected immunosuppressants, tacrolimus, sirolimus and cyclosporin A in whole blood. Experimental results being presented include serum and whole blood calibra8on curves and the analysis of commercially available quality control samples.

AB Sciex UK Ltd

T2: Cliquid™ and iMethods™ - LC-MS/MS solu0ons for clinical research Dan Leigh, Senior Applica2on Specialist

12.40-12.55

The Binding Site

13.05-13.20

DiaSorin

13.30-13.45

14.55-15.10

T3: Introduc0on to heavy-light chain (Hevylite) assays and their clinical applica0ons Alison Levoguer, Scien2fic Affairs Manager, The Binding Site This talk will focus on the development, analy8cal valida8on and ini8al clinical data published on the novel IgG, IgA and IgM heavy-light chain assays. T4: An introduc0on to the LIAISON XL® Darren Tomlinson Please join us for a brief introduc8on to the LIAISON XL® our new, high throughput, random access immunoassay analyser. We took what made the LIAISON® so successful and combined that with cu:ng-edge so(ware and hardware design, producing the first single immunoassay pla7orm allowing consolida8on of specialist and rou8ne work.

Menarini Diagnos0cs Ltd

T5: What is the future for HbA1c tes0ng? Stuart Chisnall, Product Manager, Menarini Diagnos8cs WHO have recently recommended that HbA1c is used to diagnose diabe8cs. What methods are available to detect HbA1c and what are the differences between them? Which method should a laboratory use to measure HbA1c? Is there an ideal instrument?

AB Sciex UK Ltd

T6: Analysis of Vitamin D metabolites by tandem mass spectrometry and online extrac0on Dan Leigh, Senior Applica2on Specialist It is of increasing interest in the clinical research laboratory to consider tandem mass spectrometry as an analy8cal technique for the analysis of steroids. We present here a summary of solu8ons offered by AB Sciex for these some8mes challenging applica8ons.

11.00-11.15

Menarini Diagnos0cs Ltd

W1: What is the future for HbA1c tes0ng? Stuart Chisnall, Product Manager, Menarini Diagnos2cs WHO have recently recommended that HbA1c is used to diagnose diabe8cs. What methods are available to detect HbA1c and what are the differences between them? Which method should a laboratory use to measure HbA1c? Is there an ideal instrument?

11.25-11.40

The Binding Site

12.40-12.55

Bayer HealthCare

13.05-13.20

13.30-13.45

W2: Introduc0on to heavy-light chain (Hevylite) assays and their clinical applica0ons Alison Levoguer, Scien2fic Affairs Manager, The Binding Site This talk will focus on the development, analy8cal valida8on and ini8al clinical data published on the novel IgG, IgA and IgM heavy-light chain assays. W3: Hypogonadism, insulin resistance and cardiovascular risk Dr R Ajjan, Senior Lecturer/Consultant in Diabetes and Endocrinology, St James Hospital, Leeds Cardiovascular disease remains the main cause of mortality in individuals with diabetes. Insulin resistance represents a key mechanism in the pathogenesis of type 2 diabetes and also plays a central role in vascular pathology. In this presenta8on, the evidence linking hypogonadism in men to insulin resistance will be presented, data on testosterone levels in diabetes reviewed and the effects of testosterone replacement therapy on cardiovascular risk discussed.

ScheBo® • Biotech UK Ltd

Focus 2011 | Exhibi8on | snippets@Focus

Wednesday 25th May

W4: A quick and easy ‘new genera0on’ test for colorectal cancer Ivor Smith, Managing Director, ScheBo® • Biotech UK Ltd The launch of the new ScheBo® • M2-PK Quick™ ‘rapid test’ brings benefits for clinical biochemists, pa8ents and doctors. Quick and easy to perform on a small ‘one-off’ stool sample, this is a sensi8ve and specific non-invasive test which facilitates the iden8fica8on of those who require further inves8ga8on for colorectal cancer, polyps or other significant gastrointes8nal diseases.

AB Sciex UK Ltd

W5: Liquid chromatography-tandem mass spectrometry solu0ons for steroid analysis Dan Leigh, Senior Applica2on Specialist

31

Focus 2011 | Exhibi8on | snippets@Focus

32

Thursday 26th May 11.25-11.40

Agilent Technologies

Th2: Agilent Technologies Clinical Applica0ons Including 1,25-Dihydroxyvitamin D3 and D2 Peter Christensen/Ashley Sage Agilent Technologies has a range of clinical applica8ons covering the analysis of Immunosuppressants, cor8sol, 25-OH Vit D2/D3, metanephrine, methylmalonic acid, homocysteine, drugs of abuse and THC. Using the new Agilent 6490 Triple Quadrupole instrument, a method has been developed for the quan8fica8on of 1,25-Dihydroxyvitamin D3 and D2 down to 10 pg/ml in plasma/serum. We will discuss what Agilent has to offer in regards to clinical analysis in terms of LC-MS instrumenta8on and clinical methods.

12.40-12.55

The Binding Site

13.30-13.45

CitySprint Healthcare

Th3: Introduc0on to heavy-light chain (Hevylite) assays and their clinical applica0ons Alison Levoguer, Scien2fic Affairs Manager, The Binding Site This talk will focus on the development, analy8cal valida8on and ini8al clinical data published on the novel IgG, IgA and IgM heavy-light chain assays. Th5: Improving transparency and tracking of pathology samples and clinical trials Andy Turner, Healthcare Director, CitySprint With an innova8ve, industry-leading tracking technology, designed to ensure a secure chain of custody, CitySprint Healthcare delivers full transparency and traceability during the secure and 8mely transporta8on of all your medical specimens and clinical trial drugs. Our solu8on can also op8mise transporta8on routes, whilst increasing security and pa8ent care.

Clinical Studies

1

2

3 4

5

6

How quickly can hypoparathyroidism resolve following correction of hypomagnesaemia? TJ Morris, G Horsman, Manchester

Loss of glycaemic control in type I diabetes due to the late development of anti-insulin antibodies DJ Halsall, P Barker, KA Burling, R Semple, Cambridge When is ethylene glycol poisoning not ethylene glycol poisoning? GM Frederick, N Selby, N Lawson, Derby

Pseudohypertriglyceridaemia follow up investigations are essential S Agalou, M Glynn, H Mundy, F Carragher, London

A case of type I (distal) renal tubular acidosis with co-existing vitamin D deficiency as presenting features of a systemic autoimmune disease PJ Monaghan, D Kannappan, D Darby, G Brabant, Manchester A rare paediatric case of familial paraganglioma in two sisters P Macdonald, L Tetlow, P Birchenough, A Kelsey, P Reed, Manchester

Sponsored by

Audit

7

8

9 10 11

12

Hospital-acquired iatrogenic hypernatraemia: how big a problem? MP Cornes, C Tomkins, P Gosling, Wolverhampton Diagnosing diabetes in Bolton primary care: the hunt for the missing million E Hinchliffe, AC Hutchesson, GE Wieringa, Manchester An audit of investigation and management of patients with severe hyponatraemia AS Azam, H Rickhuss, M Labib, Dudley Auditing NT-proBNP requesting in primary care patients under 60 JJ Scargill, Blackburn

Systematic audit of patients with equivocal troponin T levels using a new high-sensitivity assay S Costelloe, M Sharifi, S Mehta, M Connell, J Wells, S Sood, R Rakhit, M Thomas, D Nair, London The effect of introduction of a highly sensitive troponin T assay on the prevalence of myocardial infarction in two Yorkshire hospitals W Mbagaya, D Narayanan, E Kilpatrick, P Poon, Scarborough

Focus 2011 | Posters | ACB Poster Prizes

ACB Poster Prizes

33

Focus 2011 | Posters | Tuesday

34

Posters Tuesday Paediatrics & IEM

T1

T2

T3 T4

T5

T6

T7

T8

T9

T10 T11

T12

T13

Investigating hypoglycaemia in infancy using guidelines and packs TF Lang, Durham

A new reversed-phase LC-MS/MS cardiolipin assay for the diagnosis of Barth syndrome A Bowron, R Frost, V Powers, P Thomas, S Heales, C Steward, Bristol

Isolated high urinary thymine in a child undergoing anti-HIV prophylaxis R Srivastava, J Mckechnie, P Galloway, Glasgow Stability of bloodspot samples for galactosaemia screening using the Beutler test: implementing the new PKU screening algorithm E Robinson, RL Jones, K McNally, P Newland, Liverpool

Newborn bloodspot result messaging pilot: a first of type project LM Shapiro, M Tolson, P Tarn, P Richardson, Leeds Performance of Advia 2400 vanadate oxidation method for the measurement of direct bilirubin in paediatric samples unprotected from light R Azad, K Johnson, D Robertshaw, Bradford

The importance of urine analysis in the diagnosis of metabolic disorders in two cases of unexpected death in childhood V Powers, A Bowron, L Goldsworthy, G Haythornthwaite, G Pierre, J Stone, Bristol Purine nucleoside phosphorylase deficiency: a mutation update PL Walker, A Corrigan, M Arenas, E Escuerdo, L Fairbanks, A Marinaki, F Carragher, London

HPRT deficiency: identification of twenty-four novel variants including an unusual deep intronic mutation A Corrigan, PL Walker, E Escuerdo, M Arenas, L Fairbanks, A Marinaki, F Carragher, London Evaluation study for the GSP Neonatal IRT kit CA Dibden, S Ellin, M Downing, J Bonham, Sheffield

Method comparison of glutarylcarnitine: is there a need for a more standardised approach? CJ Gallagher, J Leakey, S Heales, F Carragher, R Carling, London Urinary reducing substances (URS) testing: time to review our practice? K Davis, K Witek, D Cregeen, M Jackson, R Carling, M Champion, F Carragher, London

A blue baby presenting with methaemoglobinaemia CM Lippiatt, AM Grove, P Walker, M Jordaan, Wakefield

Methods

T14

T15

T16

T17 T18

T19 T20 T21

T22

T23 T24

T25

T26 T27

Semi-automated reflex testing for on line SPE LC-MSMS: cascade testing to eliminate 3-epi 25 hydroxyvitamin D3 interference M Wright, KP Taylor, DJ Halsall, Cambridge

Measurement of urinary 5-hydroxyindole acetic acid using online solid phase extraction coupled liquid chromatography-tandem mass spectrometry SR Wickramasinghe, Z Arkir, London Determination of the reference ranges of urine calcium to creatinine ratio in healthy adults KM Stepien, P Prinsloo, P Gupta, N Dennis, T Hitch, Nottingham

Evaluation of the Abbott Architect 25-OH vitamin D assay JR Bailey, RS Chapman, M Donaldson, London

Performance of the Abbott Architect 25-OH vitamin D assay in DEQAS JR Bailey, RS Chapman, M Donaldson, JC Jones, GD Carter, London Procalcitonin stability in serum and plasma JC Clayton, LJ Wilson, JG Cunniffe, M Leonard, Wirral

Effect of MRM transition on 25-hydroxyvitamin D3 and D2 measurement by LC-MS/MS RL Shea, L Ford, JD Berg, Birmingham

Evaluation of an LC-MS/MS method for sirolimus in whole blood MM MacMahon, K Mulready, M Fitzgibbon, Dublin, Ireland A comparison of the measurement of testosterone by two immunoassay systems AP Courtney, P Holloway, S Barnes, London

The effect of acidification of urine on calcium and phosphate measurement AP Courtney, P Holloway, S Barnes, London

The high sensitivity troponin T assay detects troponin in pure water, could the assay be made any more sensitive? J Jeffery, F Mills, V Clough, R Ayling, H Delaney, Plymouth Troubleshooting an HPLC with Coulochem, electrochemical detection assay for urine 5HIAA S Hatch, G Higgins, D Fairclough, NB Roberts, Liverpool

Developing a spectrophotometric method for detecting foetal haemoglobin in stool samples T Hitch, V Thurston, Nottingham An evaluation of two enzyme-linked immunosorbent assays for the measurement of insulin-like growth factor-II in serum SJ Redding, G Wark, C Livingstone, Guildford

T29

T30 T31

T32 T33

T34

T35

T36

T37 T38

T39

T40

T41

Simultaneous analysis of cortisol and cortisone in saliva using liquid chromatography-tandem mass spectrometry with online solid phase extraction RL Jones, LJ Owen, JE Adaway, BG Keevil, Manchester

T43

Development of a chemiluminescent immunoassay for chromogranin A C Searell, C Evans, I Weeks, Cardiff

T45

Salivary cortisol and cortisone by UPLC tandem mass spectrometry: establishing a reference range for use in screening for Cushing’s syndrome V Powers, A Bowron, L Owen, P Thomas, Bristol

Development and validation of a LC-MS/MS method for the measurement of plasma renin activity using on-line solid phase extraction S Carter, L Owen, B Keevil, Manchester Development of a high sensitivity oestradiol assay E Crouch, Poole

Comparison of transferrin saturations calculated by measuring transferrin and total iron-binding capacity R Wigley, S Rainbow, London

Development and validation of a method for the measurement of chromium and cobalt in whole blood J Rogers, S Smith, Cardiff

Teicoplanin measurement by LC-MS/MS: developing a novel method FHY Fung, JCY Tang, J Hopkins, L Bailey, A Davison, Liverpool

Development of a method for measuring thiopurine S-methyltransferase activity in whole blood using high-performance liquid chromatograpy with fluorimetric detection SL Davies, SJ Lockhart, BG Keevil, Manchester

Development and validation of a method for the measurement of chromium and cobalt in serum J Rogers, S Smith, Cardiff

Development and validation of a liquid chromatography-tandem mass spectrometry method for the measurement of androgens in serum R Leyland, SJ Darch, M Donaldson, London

Total and intra-individual coefficients of variation for the measurement of whole blood TPMT activity NL Barlow, V Graham, JD Berg, Birmingham

Female testosterone: are fewer discrepant results observed post-extraction after changing from Siemens Centaur to the Roche Cobas TESTO II immunoassay? S Mosaheb, Berkshire

Simultaneous measurement of prednisolone, prednisone, cortisol and cortisone by LC-MS/MS J Duffy, C Webster, Birmingham

Instrumentation

T42

How significant is evaporation from samples on a biochemistry track system? KJ Hedges, JD Berg, Birmingham

T44

Rapid, simultaneous analysis of multiple steroids in human serum by LC-MS/MS L Couchman, L Ghataore, RP Vincent, R Marsh, NF Taylor, London Marginally increasing the haemolysis index on the Roche Modular analysers significantly reduces the number of samples unsuitable for serum LDH and folate analysis M Livingston, JM Forsyth, Derby

Evaluation of the IDS iSYS hGH and IGF1 assays RL Allcock, P Page, S Kaleem, MA Myers, Preston

Point of Care Testing

T46

T47 T48

T49 T50

T51

T52

T53

T54 T55 T56

Point of care urinalysis: an examination audit F Siddique, J Tatton, E Laverick, C Ford, Wolverhampton An early warning score system for glucose using Roche Inform glucose meters P Ridgwell, N Smith, D Cannon, Luton

Impact of analytical performance of point of care blood glucose meters on application of a ‘tight glycaemic control’ protocol in an intensive care unit setting M Ryan, P McBride, R Calderwood, Antrim Qpoint: a user friendly EQAS for blood glucose meters KL Whiting, Camberley

Focus 2011 | Posters | Tuesday

T28

A comparative evaluation of the Cholestech LDX and CardioChek PA point-of-care testing lipid and glucose analysers SJ Whitehead, C Ford, R Gama, Wolverhampton

A pragmatic study of the diagnostic performance of a urine albumin-to-creatinine ratio point-of-care test for use in the detection of albuminuria MP McTaggart, RG Newall, CP Price, PE Stevens, RG Pinnock, EJ Lamb, Ashford A false negative pregnancy test within the A&E Department using point-of-care testing JL Williams, V Lane, A Singal, JD Berg, Birmingham

Implementation of data networked urine strip readers in an emergency surgical admissions ward I Smith, D Bishop, K Paddon, J Kay, C Mevada, Oxford

Patients do it at home! Home testing kits: are consumers truly informed? H Kinns, N Smith, D Housley, DB Freedman, Luton Quality of point of care urinalysis and the need for improvement C Glicksman, F MacKenzie, S Davie, London

Innovative POCT co-ordinator reports from UK NEQAS J French, F MacKenzie, A Robins, Birmingham

Quality Assurance

T57

Development of an automatic flagging system to identify potentially “hooked” urine albumin samples NJ Gilberthorpe, T Hitch, Nottingham

35

Focus 2011 | Posters | Tuesday

36

T58

T59 T60 T61 T62

Development of an external quality assessment scheme for serum angiotensin converting enzyme GJ Davies, MA Thomas, Cardiff

Impact of introduction of a zero tolerance policy on request form error rates in a DGH setting MF Ryan, M Entwistle, G Kennedy, Antrim

Monitoring FOBT positivity in the national bowel cancer screening programme C Burtonwood, SP Halloran, P Butler, Guildford Non-specificity of creatinine assays probed by UK NEQAS; even glucose can interfere! F MacKenzie, Birmingham Innovative laboratory network reports from UK NEQAS F MacKenzie, J French, A Robins, Birmingham

Audit

T63

T64 T65 T66 T67

T68

T69 T70

T71

T72 T73

T74

Faecal occult blood test audit A Kiley, T Everitt, Westcliff-on-Sea

Anyone for TPMT? An audit of TPMT requesting at Southend Hospital A Kiley, L Cranfield, Westcliff-on-Sea

Audit of serum free light chains requests in a District General Hospital C Soromani, P West, J Luckit, N Rabin, London

Audit of thiopurine methyltransferase requests in a District General Hospital C Soromani, P West, London

A clinical audit of total parenteral nutrition support in University Hospital Lewisham E Fung, SR Wickramasinghe, J Panteli, M Crook, London The general practioners and the challenge of hypertriglyceridaemia: the scorers, the losers and the spectators AM Hassan, H Griffths, P Cooney, Manchester

Appropriateness of tumour marker requesting in a district general hospital LG Hawkins, P West, Tunbridge Wells

Audit of AST and the liver function profile at the Royal Free Hampstead NHS Trust S Costelloe, M Connell, R Browne, M Thomas, London Audit of CK-MB requesting and clinical use at the Royal Free Hampstead NHS Trust S Costelloe, M Connell, J Wells, M Thomas, London An audit of requests for the oral glucose tolerance test in a district general hospital PS West, London

An audit of requests for androstendione and dehydroepiandrosterone sulphate in a District General Hospital PS West, J Emmanuel, H Kuhan, London

The utility of plasma metanephrine measurement in the detection of phaeochromocytoma A Abdel-Razik, P Reed, MF Stewart, Manchester

T75

T76

T77

T78 T79

T80 T81 T82

T83 T84

T85

T86

T87

T88 T89 T90

Audit of CRP requesting by the Emergency Department LJ Hikin, N Stockdale, DT Vallance, MH Labib, Dudley Audit of oral glucose tolerance tests in primary care O Clifford-Mobley, N Sawyer, F Riddoch, S Davie, London

“Add-on” test requests: are samples stored on sample manager modules suitable for delayed analysis? RL Kift, SR Goodall, Leeds

Managing demand for thyroid function tests: a re-audit MC Davies, Crewe

Transport of samples by pneumatic tube does not significantly increase the tendency for haemolysis C Treslove, M Guy, Salford

Too much of a good thing? An audit of inappropriate phlebotomy at Aintree SL Hanton, CA Chadwick, A Wootton, Liverpool Audit of criteria used in haemochromatosis genotype testing TJ Morris, G Horsman, Manchester

Implementing cascade screening for familial hypercholesterolaemia in times of austerity: an audit of current practice TJ Morris, G Horsman, Manchester Audit of NT-proBNP requesting in Hull and East Yorkshire CL Rigg, K Smith, I Hanning, Hull

An audit of the clinical incidents occurring within the Department of Clinical Biochemistry at East Kent Hospitals University NHS Foundation Trust MP McTaggart, SL Stock, Ashford An audit of impaired glucose regulation monitoring following an oral glucose tolerance test M Sargazi, WD Neithrcut, Wirral

Demand management of GI tumour markers (CEA and CA19-9) requests L Tibi, L Calonzo, I Chandarana, S Catnach, Hemel Hempstead

All-Wales audit of method-dependent TSH assay bias and use of TSH decision limits for guiding treatment of subclinical hypothyroidism as defined by ACB/BTA thyroid guidelines (2006) KL Parham, DH Ducroq, MA Thomas, C Evans, Cardiff The use of educational comments in limiting inappropriate tumour marker requests E Moody, D Powell, A Rudenski, Manchester An audit of the appropriateness of primary and secondary care vitamin D requesting FA Davidson, A Day, Weston-super-Mare

Audit of paediatric methotrexate requests May 2009 - April 2010 to determine expected results patterns A Sarker, A Gidman, A Park, Cambridge

T92

T93 T94

The effect of local guidelines on tumour marker requesting: a retrospective audit R Leyland, N Martin, N James, D Wickens, P Leonard, London

T95

An audit of the use of tumour markers against national, local and laboratory guidelines RS George, J Wassell, R Goodall, Bristol

T97

Serum uric acid: an overlooked co-morbidity marker in the assessment of patients for bariatric surgery K Stuart, A Abeysekera, M Labib, Dudley

Measurement of chromogranin B has limited clinical utility for monitoring patients with NETs: a 3 year retrospective audit in a tertiary referral centre PJ Monaghan, JW Valle, W Mansoor, PJ Trainer, D Darbym, Manchester

T96

T98

Is venepuncture technique a contributory factor in high rates of A&E sample haemolysis? AM Parasram, A Everitt, T Hogan, L Abdullam, Basildon The clinical significance of low alkaline phosphatase results in adults and children and the suitability of current reference ranges P Mohammed, A Wall, JD Berg, Birmingham Hospital in-patients with hyponatraemia: could we do better? AS Davison, C Iqbal, T Purewal, E Marks, Liverpool Audit of the short synacthen test KK Chatha, C Webster, Birmingham

Focus 2011 | Posters | Tuesday

T91

37

Focus 2011 | Posters | Wednesday

38

Posters Wednesday Bone Disease & Calcium Metabolism

W1 W2

W3

W4 W5

Repeat requesting of 25-hydroxyvitamin D in a UK District General Hospital T Teal, R Travers, Winchester

Biochemical effectiveness of a high dose oral vitamin D supplementation protocol® for treating hypovitaminosis D RP Vincent, MO Elnenaei, D Shipnaugh, R Chandra, C Moniz, London

Clinical relevance of serum total 25-hydroxyvitamin D as measured by two immunoassays and TurboFlowTM LC-MS/MS L Couchman, R Musto, RP Vincent, R Clarke, R Langworthy, C Moniz, London

Vitamin D and antiepileptic treatments R Patle, R Inaoui, L Nashef, C Moniz, London

Effects of vitamins D2 and D3 on osteoblast differentiation and activity F Lam, A Zarei, D Mahoney, G Mabilleau, A Sabokbar, A Morovat, Oxford

Cardiovsacular

W6

W7

W8

W9

W10

W11

W12 W13

A study of insulin-like growth factor binding protein-2 as a marker of insulin sensitivity in Saudi and Caucasian subjects MRR Self, G Wark, A Borai, S Shafi, G Ferns, C Livingstone, Frimley

An audit of serial high-sensitivity troponin T measurements for early diagnosis of myocardial infarction in the Emergency Department JL Waldron, C Webster, J Alan, Birmingham

A comparison of biochemical markers for cardiovascular risk in Southern Asians and Northern Europeans based in the UK H Sawney, D Gaze, P Collinson, London The effect of fibrate treatment for hyperlipidaemia on serum creatinine and cystatin C V Ncube, B Starkey, T Wang, Frimley

First-line screening for heart failure with brain natriuretic peptide: a costly strategy? A Rudenski, J Scargill, P Woolfson, M Guy, Salford Clinical impact of using the troponin I 99th percentile cut-off for diagnosis of acute coronary syndrome S Zouwail, M Wasik, G Davies, Cardiff

A rare case of tendon xanthomata M Balasubramani, C Dawson, K Crudgington, G Bayly, Bristol

Genotype-phenotype correlation in familial hypercholesterolaemia: a snapshot from the South West of England M Balasubramani, L Yarram, M Williams, S Humphries, G Bayly, Bristol

W14 W15 W16 W17

Investigation of the incidence of macrotroponin-T in the Roche high sensitive troponin-T assay L Hawke, N Lawson, J Forsyth, L Clark, Derby Trends in the specialist referrals and treatment of familial hypercholesterolaemia MJ Turzyniecka, TA Gray, Sheffield Implementation and use of the highly sensitive troponin T assay K Smith, DJ Andrews, R Cramb, Birmingham

Biochemical changes associated with weight loss in obese subjects M Ryan, DC Flanagan, C Torrens, DO Finnegan, Coleraine

Diabetes

W18 W19

W20

W21

W22

W23

W24

W25

W26 W27

Combination of HbA1c and blood glucose improves diagnosis of diabetes mellitus M Ryan, R Nicholl, R Calderwood, Antrim

12-year audit of metabolic and glycaemic control in a DGH out-patient diabetic population against primary care QoF standards of care M Ryan, S Kassim, LK Diong, Coleraine

Variant haemoglobins identified when asymmetrical peaks produced by IE HPLC for HbA1c SE Manley, CL Mason, RA Round, BN Green, P Narendran, R Cramb, Birmingham

Rare, ‘fast’ haemoglobin variants detected by high performance liquid chromatography analysis performed for HbA1c measurement S Misra, MR Hancock, London

Urinary bile acids are increased in type 2 diabetes mellitus D Taylor, J Alaghband-Zadeh, R Sherwood, L Alexander, C Stone, C Moniz, C le Roux, London Glycated haemoglobin: a reliable marker of insulin resistance in subjects with normal glucose tolerance AA Borai, C Livingstone, G Ferns, Jeddah, Saudi Arabia

Insulin sensitivity (HOMA-S) predicts HbA1C reduction with a GLP-1 analogue AH Heald, RP Narayanan, D Lowes, E Jarman, SG Anderson, D Oleesky, M Davies, MZ Qureshi, Crewe Use of fasting glucose concentrations in antenatal glucose tolerance tests C Glicksman, T Brooker, F Riddoch, S Davie, D Simms, London

Are clinicians ready for the transition to sole IFCC reporting of HbA1c? B Jones, C Meek, G Ball, London

Lipid monitoring in diabetes: failure to request a full lipid profile is resulting in inaccurate monitoring in relation to the NICE clinical guideline target S Hultin, AP Day, Weston-super-Mare

W29

W30

W31

The use of serum C-peptide levels for the classification of diabetes mellitus SJ Redding, G Wark, C Livingstone, Guildford

W42

Inappropriate pathology testing: using diabetes as a model to assess prevalence, impact of national guidance and practice-to-practice variability OJ Driskell, D Holland, FW Hanna, PW Jones, J Pemberton, M Tran, AA Fryer, Stoke-on-Trent

W44

Considerations for safe and effective use of glycated haemoglobin in the management of patients with diabetes mellitus D Church, DJ Halsall, D Simmons, Cambridge

Oral glucose tolerance tests: are biochemistry labs setting the best example? DM Kennedy, L Jerrom, C Pitt, Birmingham

W43

W45 W46

Endocrinology

W32

W33

W34

W35

W36 W37

W38

W39

W40

W41

Cushings with a catch S Mapplebeck, K Metcalf, C Corns, Southend

The relationship between serum TSH and free T4 in the elderly PM Clark, R Holder, S Haque, R Hobbs, LM Roberts, JA Franklyn, Birmingham Elderly Thyroid Study Team, Birmingham Significant hypertestosteronaemia with a lack of virilisation in a female patient with chronic liver disease H Divyateja, V Thurston, NJ Gilberthorpe, S Page, N Taylor, T Hitch, Nottingham

Synthetic macroprolactin: characterization of a human serum based prolactin-mouse monoclonal antibody complex DJ Halsall, SJ Oddy, K Gordon, AR Ellis, M Fahie-Wilson, PM Clark, Cambridge

Should SHBG be measured routinely in the investigation of female hyperandrogenaemia? K Smith, J Shepherd, E Kilpatrick, Hull

Morbidity and mortality of infants with salt wasting congenital adrenal hyperplasia in an unscreened population BE Hird, L Tetlow, L Patel, S Tobi, P Clayton, Manchester

The biological variation of IGF-1 in stable acromegaly SJ Glover, R Murray, SN Mohammad, JH Barth, Leeds

Clinical performance of the Roche Cobas e411 automated assay system for TSH-receptor antibodies for the diagnosis of Graves’ disease NR Syme, AD Toft, M Stoddart, GJ Beckett, Edinburgh Method-specific normal cortisol response to the short Synacthen test N El-Farhan, A Pickett, D Ducroq, K Parham, C Bailey, A Armston, N Morgan, DA Rees, C Evans, Cardiff

A rare case of hyperandrogenism in a female phenotype H Divyateja, N Greig, S Page, T Hitch, Nottingham

W47 W48

W49 W50

W51

W52

W53 W54

Gut

W55

W56

Revision of androgen reporting limits at Salford Royal Hospital D Turnock, J Kane, A Rudenski, Salford

Cushing’s disease in a three year old girl: the case of the missing tumour E Robinson, P Dharmaraj, J Blair, P Newland, Liverpool

Simultaneous analysis of steroid panel in human serum by LC-MS/MS: comparison with immunoassay L Ghataore, L Couchman, RP Vincent, R Marsh, C Moniz, NF Taylor, London First trimester reference ranges for thyroid function tests LK Stokoe, SD Troup, S Razvi, Gateshead

The ratio of LH to FSH measured in women with hyperandrogenaemia is dependent on the analytical platform used M Gotseva, M Davies, A Cooper, P Byrne, D Oleesky, A Heald, I Laing, Crewe

Macroprolactin: validation of the PEG precipitation assay and a survey of 18 months in practice NJ Rankin, S Zaman, AA Fryer, Stoke-on-Trent Prevalence of congenital hypothyroidism in infants presenting with prolonged jaundice FM Ivison, S Gopalkothandapani, I Banerjee, L Tetlow, Manchester

Clinical significance of low testosterone values in men aged 20 to 50 years old G Dodds, J Shepherd, D Narayanan, Hull

Focus 2011 | Posters | Wednesday

W28

Urine steroid profiling in pituitary and adrenal Cushing’s syndrome RP Vincent, J Alaghband-Zadeh, CW le Roux, C Moniz, KM Schulte, SJ Aylwin, NF Taylor, London A dose-dependent interference in the immunoassay of serum cortisol by the 11β-hydroxylase inhibitor metyrapone PJ Monaghan, LJ Owen, PJ Trainer, G Brabant, BG Keevil, D Darby, Manchester Primary autoimmune thyroid disease with isolated secondary adrenal deficiency and high background autoimmunity: an unusual combination H Sharma, M Sharma, S Bulusu, London

Antiretroviral drugs and biochemistry tests: need for caution when interpreting results SS Min, S Bulusu, London

Determining calculated free testosterone reference ranges in an adult male normal population using the Roche E170 testosterone II method S Haslam, N Hunt, M Myers, Preston Review of clinical utility of alpha-1-antitrypsin, serum copper, alpha-foetoprotein and caeruloplasmin components of ‘liver screen’ testing from the gastroenterology service in a DGH M Ryan, A Varghese, Coleraine A clinical evaluation of a new point of care testing device for faecal calprotectin J Wassell, M Wallage, E Brewer, Bristol

39

Focus 2011 | Posters | Wednesday

40

W57 W58

W59

W60

W61 W62

An audit of the pattern of test requests for tissue transglutaminase antibodies A Gbegbaje, P Bourne, Crewe

Faecal inflammatory markers in children with Crohn’s disease CP Glenn, AE Wiskin, F Majid, RM Beattie, SA Wootton, Southampton

Proton pump inhibitors and hypomagnesaemia: a case for PPI inhibiting magnesium absorption from GI tract I Bailey, Bromley Calprotectin and inflammatory bowel diseases: Isle of Wight experience A Al-Bahrani, L Grellier, C Sheen, C Tracey, A Domanski, Newport, Isle of Wight A service evaluation of faecal sugar chromatography JD Spencer, MJ Henderson, Leeds

Comparison of the diagnostic performance of transient elastography and non-invasive fibrosis scoring systems in patients with biopsy proven non-alcoholic fatty liver disease I Barnova, BH Lopez, R Przemioslo, London

Nutrition

W63

Changes in asymmetric dimethyl arginine and nitric oxide post-bariatric surgery R Patle, S Dubb, J Alaghband-Zadeh, R Sherwood, F Tam, A Frankel, M Bueter, CW le Roux, London

Acute Medicine

W64

W65

W67

W68 W69

W70

W72

W73

An audit of the outcome of severe hypernatraemia in hospitalised patients A Sanders, D Vallance, M Labib, Dudley

The evaluation of population characteristics in a patient cohort attending a routine specialised lipid clinic at a university hospital KM Stepien, H Divyateja, P Prinsloo, P Gupta, Nottingham

Inherited hypercholesterolemia due to combined LDLR mutation and FDB mutation leading to premature coronary artery disease in a young man D Chandrajay, A Waise, York Standards for lipid analysis and reporting: can we achieve a consensus? SJ Pattman, RDG Neely, Newcastle-upon-Tyne

A study to establish factors associated with fibrate induced elevation in creatinine A Abbas, J Raju, S Ramachandran, S Saraf, S Ramachandran, Sutton Coldfield

Significant increase in HDL cholesterol is associated with low pre-treatment HDL cholesterol following fibrate therapy S Saraf, J Raju, A Abbas, A Jones, S Ramachandran, Sutton Coldfield

Effect of historical changes in HDL-cholesterol measurements on cardiovascular risk assessment R Marrington, C Webster, C Jewkes, WA Bartlett, A Jones, Birmingham The role of lipoprotein (a) in clinical biochemistry laboratories R Marrington, C Webster, C Jewkes, A Jones, Birmingham

Are our HDL-C methods fit for purpose? R Marrington, J French, C Webster, C Jewkes, WA Bartlett, A Jones, Birmingham

Oncology

W74

W75 W76

W77

A survey of users of an SAS thyroglobulin service K Gordon, Birmingham Elevated amylase in a patient with IgA-k myelom M Sargazi, N Butt, M Leonard, Wirral

Pancreatic cyst fluid CA19-9; a useful investigation? R Langworthy, A Gera, J Devlin, R Sherwood, London Interference in PSA immunoassays D Church, P Barker, KP Taylor, DJ Halsall, Cambridge

Haematology

W78

W79

Atypical presentation of myocardial tuberculosis KM Stepien, Nottingham

Lipids

W66

W71

People, places and parasites: over 30 years of malaria investigation KL Williams, C Taylor, J Myburgh, Gillingham How well do we manage newly diagnosed myeloma and MGUS patients?: a 12 month audit of patient follow-up P Mohammed, L Hackett, Y Shakil, A Wall, JD Berg, Birmingham

Clinical Studies

W80 W81

W82

W83 W84

W85

Evidence of caffeine abuse in at-risk populations KJ Hedges, JD Berg, Birmingham

Evaluation of a kisspeptin assay as a screening tool for pre-eclampsia JJ Logie, SC Riley, FC Denison, JE Norman, RM Reynolds, Wishaw Self referral for health-related problems associated with alcohol misuse in Birmingham P Kampanis, E Furlong, G Georgiou, A Wall, J Berg, Birmingham The management of ethylene glycol poisoning on a general paediatric ward G Hann, D Duncan, D Sohi, P West, London

Tragedy strikes twice: two cases of long chain 3 hydroxyl acyl coenzyme A dehydrogenase deficiency occuring in the same family P West, T Bycroft, V Jones, London Defining suitable reference intervals for creatinine, thyroid stimulating hormone, free thyroxine and urate in pregnancy B Shine, S French, M Mirzazadeh, T James, I Smith, L MacKillop, JD Kay, Oxford

Renal Disease

Th1

Th2

Th3

Th4

Th5

Th6

Th7

Th8 Th9

Serum levels of troponin I in patients with renal failure F Stratford, Y-Q Wong, T James, R Morovat, B Shine, Oxford Acute kidney injury with tubulointerstitial nephritis and excess oxalate crystals: how toxic is vitamin C and sclerotherapy? KM Stepien, R Sims, T Hitch, P Prinsloo, Nottingham

A study into the biological variation of bone-specific alkaline phosphatase activity amongst stable haemodialysis patients S Sardiwal, PE Stevens, MP Delaney, EJ Lamb, Canterbury Comparability of CKD-EPI and MDRD equations in a large UK cohort: what is the impact of age? JL Carter, PE Stevens, J Irving, EJ Lamb, Canterbury High sensitivity troponin T concentrations increase as renal function declines and are significantly affected by haemodialysis GC McKeeman, M McDonnell, P Archbold, G Connolly, B Roberts, E Hanna, D Fogarty, Belfast

A comparison of ACR and PCR measurement in the detection of proteinuria MP McTaggart, RG Newall, CP Price, PE Stevens, RG Pinnock, EJ Lamb, Ashford Introduction of iohexol glomerular filtration rate into paediatric clinical practice K Mitchell, R Hitchcock, C Mevada, J Taylor, J Craze, T James, Oxford

How well is acute kidney injury identified in an acute general hospital? ID Watson, A Fazleen, Southport

Acute kidney injury: real-time identification and monitoring using APEX iLab J Monaghan, B Rai, N Selby, L Crowley, R Fluck, N Lawson, Derby

Th10 Verification of the urinary neutrophil gelatinase-associated lipocalin assay performance on the Abbott ARCHITECT i1000sr R Cullen, M Fitzgibbon, Dublin, Ireland

Th11 The effects of goal directed therapy on kidney injury as measured by urine neutrophil gelatinase-associated lipocalin in patients post-major abdominal surgery R Cullen, S Jhanji, R Pearse, M Fitzgibbon, Dublin, Ireland

Th12 Accuracy of the MDRD and CKD-EPI GFR-estimating equations in older people EJ Lamb, H Kilbride, G Eaglestone, S Knight, MP Delaney, CK Farmer, SE O'Riordan, RN Dalton, PE Stevens, Canterbury

Th13 Method differences in parathyroid hormone concentrations in patients with chronic renal failure: implications for patient care and an interim solution A Ellis, S Walker, A Almond, Edinburgh

Th14 Automated ammonia assay: evaluation and application to investigate whether ammonia levels are influenced by kidney function S Nundlall, A Milan, S Philips, L Bailey, M Howse, N Roberts, Liverpool

Th15 Effects of changing from the modification of diet in renal disease equation to the chronic kidney disease epidemiology collaboration equation on the classification of patients into the different stages of chronic kidney disease B Shine, CA O’Callaghan, DS Lasserson, Oxford Th16 eGFR: what next? OJ Driskell, FW Hanna, AA Fryer, Stoke-on-Trent

Proteins/Enzymes

Th17 Cryoglobulin requesting at Southend Hospital NHS Trust S Mapplebeck, Southend

Focus 2011 | Posters | Thursday

Posters Thursday

Th18 Glycosylation of IgG paraproteins: a potential marker of malignancy JA Schroeder, S Fleming, Redditch

Th19 Cryofibrinogen: clinical and analytical aspects H Sharrod, M Saas, H Barbour, Southampton

Th20 An audit of the electrophoresis comments reported across the Essex Chemical Pathology Network laboratories SK Moore, AS Everitt, G Brindle, Essex Th21 The impact of the introduction of the Sebia Capillarys2 on the number of serum protein electrophoresis samples selected for immunofixation JM Armer, D Paisley, JE Hogg, Glasgow

Th22 Manipulation of the active site of human glycolate oxidase to assess the role of long-chain hydroxy-acid oxidase in glyoxylate metabolism N Unsworth, G Rumsby, EL Williams, London

Th23 Can you add to your service by immunosubtraction? JM Armer, D Paisley, JE Hogg, Glasgow

Th24 Stability of whole blood TPMT enzyme activity under conditions experienced during transit NL Barlow, V Graham, R Shadra, JD Berg, Birmingham

Toxicology/TDM

Th25 Colloidal silver and catatonic schizophreniachicken or egg? KM Stepien, S Brown, Nottingham

Th26 Lead poisoning of unknown cause KM Stepien, P Morris, S Brown, L Morgan, S Page, Nottingham

41

Focus 2011 | Posters | Thursday

42

Th27 Development of a liquid chromatography tandem mass spectrometry method to measure a profile of 7 anti-epileptic drugs KJ Duxbury, CA Chadwick, Liverpool

Th28 Stability of routinely measured therapeutic drugs in the BD SST II Advance vacutainer® N Greig, L Morgan, S Brown, Nottingham Th29 Development of an enhanced LC-MS/MS method for the detection of 14 different benzodiazepines and comparison with two commercial immunoassays C Mahoney, G Waite, Salford

Th30 Assessment of Oracol+ oral fluid collection devices for measuring salivary drugs of abuse using aqueous and saliva standard curves RL Shea, S George, JD Berg, Birmingham Th31 Simultaneous measurement of cyclosporin and tacrolimus from dried blood spots by LC-MS/MS E Hinchliffe, JE Adaway, LJ Owen, BG Keevil, Manchester

Th32 Measurement of antipsychotic drugs in children and adolescents: oral fluid, capillary blood, and dried blood spots SJ Partridge, DS Fisher, RJ Flanagan, London Th33 Towards a microextraction method for salivary drugs of abuse measurement by GCMS RL Shea, S George, JD Berg, Birmingham

Th34 Development and validation of an ICP-MS method for lithium blood spot analysis P Kampanis, K Hedges, TMT Sheehan, JD Berg, Birmingham

Th35 Evaluation of different methods for carrying out unknown drugs screens in urine E Moody, G Waite, Manchester

Th36 Drug detection in oral fluids versus urine: what are the differences? H Mendoza, G Lauder, D Ajeda, B Kidd, WA Bartlett, Dundee

Th37 Taking a snapshot of occupational drug screening SA George, Birmingham

Th38 The changing pattern of drug use in the West Midlands SA George, Birmingham

Th39 The detection of antidepressant treatments in poisoning cases SA George, Birmingham

Th40 Are paracetamol and salicylate requests appropriate? HM Jopling, C Reeves, A Jones, GJ Ayers, Manchester

Th41 TurboFlowTM technology for the therapeutic drug monitoring of azole antifungal drugs S Buckner, L Couchman, C Moniz, MM Ceesay, A Pagliuca, RJ Flanagan, London

Th42 Validation of serum separator tubes for antibiotic measurement on Roche Integra LE Clark, J Johnston, J Forsyth, Derby

Th43 Development of an automated MS-based screening procedure for clinical and forensic toxicology J Kempf, S Vogt, B Saar, J Hillis, B Schneider, S Götz, Freiburg, Germany Th44 Development of a LC-MS/MS method to measure the legal high cathinone and its derivatives in the clinical laboratory J Reeve, I Clunie, L McKay, J Allison, D Stephen, Aberdeen Th45 Development of a LC-MS/MS method to measure the new psychoactive legal high methylenedioxy-2-aminoindane in the clinical laboratory J Reeve, I Clunie, L McKay, J Allison, D Stephen, Aberdeen

Trace Elements

Th46 Serum trace elements concentrations after bariatric surgery DK Papamargaritis, ET Aasheim, B Sampson, CW le Roux, London Th47 Technical evaluation of a rapid combined method for copper, zinc and selenium in serum and urine by ICPMS O Clifford-Mobley, S Whiting, London

Th48 Tissue copper concentrations in paediatric non-alcoholic fatty liver disease K Raja, E Fitzpatrick, A Dhawan, A Bomford, London

Molecular Genetics

Th49 Single nucleotide polymorphisms in the tyrosinase gene and their association with the risk of and severity of multiple sclerosis NJ Rankin, RC Strange, AA Fryer, Stoke-on-Trent Th50 Polymorphisms of the glucocorticoid receptor gene and postnatal depression L Darwin, N Engineer, N Deole, D Grammatopoulos, Coventry

Th51 A patient with the rare alpha-1-antitrypsin variant Zbristol in compound heterozygosity with the Z mutation KJ Bates, M Hill, N Kalsheker, A Barlow, B Clark, RA Sherwood, London Th52 Mutation screening in suspected familial hypercholesterolaemia in Merseyside SL Hanton, C van Heyningen, DB Wile, R Mountford, Liverpool

Th53 A simple and rapid method of genotyping a common variant in the FTO gene that predisposes to childhood and adult obesity JP Smith, A Shoukry, D Vallance, M Labib, Dudley

Th54 Development of an assay for the genetic diagnosis of 17β-hydroxysteroid dehydrogenase type 3 deficiency G Esmaeil Pourmahram, E Williams, G Rumsby, Hertfordshire

Th56 Comparison of eight pharmacogenetic algorithms for the prediction of warfarin dose FA Davidson, R Goodall, Bristol

Management

Th57 Sample centrifugation in primary care H Turner, K McCurrach, I Philip, J Allison, Aberdeen

Th58 Tackling demand management with a double-edged sword: successful pilot of ‘vetting’ referred-out tests C Tomkins, C Darby, SCH Smith, Coventry

Th59 Critical appraisal: a simple tool to improve efficiency in the laboratory and help meet the QIPP challenge R Carling, S Agalou, A Booth, C Gallagher, M Jones, K Witek, F Carragher, London Th60 Establishment of an automated commenting system in a community pathology laboratory G Smith, K Williams, JL Barron, C Ng, Christchurch, New Zealand Th61 Self-testing by general practitioners: how extensive is it? JL Williams, JD Berg, Birmingham

Th62 Implementing operations performance management system within the laboratory K Witek, A Corrigan, S Carney, P Clements, R Carling, F Carragher, London Th63 Vitamin D: results of an individualised approach to demand management C Tomkins, J Hawley, Coventry

Th64 Excessive blood taking: enough is enough JL Williams, RK Shardra, JE Berg, Birmingham Th65 Telephoning results: a view from the other side JL Williams, JD Berg, Birmingham

Th66 Introduction of electronic requesting and demand management into the Emergency Department: does it work? C Webster, A MacNamara, R Boddy, D Husband, P Dyer, A Jones, Birmingham

Case Histories

Th67 Idiopathic hypercalcaemia in pregnancy FC Riddoch, DM Simms, MW Spring, Kingston-upon-Thames

Th68 A case of hepatocerebral mtDNA depletion syndrome due to mutations in MPV17 RL Jones, P Newland, A Morris, Liverpool

Th69 Keep your eyes open for the unusual! A hyperandrogenised 15 year old girl and the role of the clinical biochemist C Tomkins, JW Honour, I Phillips, E Helm, H Stirling, Coventry

Th70 Recognising macro-TSH: a rare cause of inappropriately high TSH values EJ Lewis, R Lim, F Joseph, D Ewins, N Goenka, SA Bowles, SA Faye, G Kertesz, Chester

Th71 Elevated ketones and ketone bodies in diabetic ketoacidosis: don’t mind the gap! TJ Morris, MA Al-Jubouri, G Horsman, Manchester Th72 A rare cause of raised alkaline phosphatase activity MP McTaggart, D Lawrence, C Rawson, M Saeed, L Miller, EM Kearney, Ashford

Th73 CA125 unsolved: an interpretative dilemma SD Harris, CM Sturgeon, AM Wayte, Bangor Th74 Thyroid function tests are not immune to misinterpretation FM Brandie, F Jenkinson, Dundee Th75 A case of newly developed heterophile antibodies to the DiaSorin Liaison 25-hydroxyvitamin D assay R Edwards, E Woolman, London Th76 A case of blue feet JD Spencer, J Walter, C Stainforth, MJ Henderson, Leeds

Th77 Severe reactive hypoglycaemia following a glucose tolerance test: a cautionary tale S Haslam, M Myers, Preston

Focus 2011 | Posters | Thursday

Th55 Real-time PCR genotyping of four SNPs associated with warfarin sensitivity and their frequency in an anticoagulated patient group FA Davidson, R Goodall, Bristol

Th78 Rhabdomyolysis due to drug interaction between simvastatin and sodium fucidate in two patients RL Allcock, J Malley, SM Rajbhandari, MA Myers, Preston

Th79 Spuriously raised serum creatinine associated with an excipient present in an IV dexamethasone formulation D Darby, J So, J Russell, PJ Monaghan, Manchester Th80 Case report: investigating a rare case of hypoparathyroidism S Nundlall, P Ivanov, WD Fraser, Liverpool

Th81 Diagnosis and management of toxic alcohol poisoning: experience of four cases TJ Morris, G Horsman, Manchester Th82 Antiretroviral drugs and biochemistry tests SS Min, S Bulusu, London

Miscellaneous

Th83 Sodium citrate contamination: how to recognise it MP Cornes, C Ford, R Gama, Wolverhampton

Th84 Short-term interventions on wards fail to reduce pre-analytical errors: results of a prospective controlled trial CE Bird, GM Kemp, JH Barth, Leeds

Th85 Patient survey: what patients expect from pathology? V Mishra, M Greenslade, M Cherry, A Herod, J Hemming, Salisbury

43

Focus 2011 | Posters | Thursday

44

Th86 The relationship between keeping a food diary and weight loss T Vidyaratne, M Labib, Dudley

Th91 A time for demand management of CRP requesting N Hunt, M Myers, Preston

Th88 BNP stability on storage: how best to handle samples? C Wright, J Meek, R Chapman, M Donaldson, London

Th93 FOB: fit for purpose? JF Doran, Swansea

Th87 Spurious hyponatraemia due to tectonic instability H Murray, G Smith, Christchurch, New Zealand

Th89 Duty biochemist: a value added service S Robinson, C Reeves, Manchester

Th90 Instability of arginine in plasma and serum samples A Crampton, G Weaving, BF Rocks, Brighton

Th92 Assessment of haemolysis index of commonly measured analytes on the Roche Modular clinical chemistry system P Mohammed, JD Berg, Birmingham Th94 NovoMix 30, Lantus and Levemir cross-reactivities with the ADVIA Centaur XP insulin assay and effects of haemolysis A Catchpole, T James, A Morovat, Oxford

Exhibition Floorplan Catering Area

39 41

36

38 40

Posters

Posters

37

35 34

33

30 29

32

31

42

Sea ng Informa on Area

Coffee Point

9

16 17

18

8

15

19

27 ACB

7 12 13 14

6 5

10

23 24

11 22

Catering Area

21

3 2

1

Kings Road Entrance

Presenta on Area

Focus 2011 | Exhibi8on | Stands

46

Conference Centre Escalator Link

C O M PA N Y

Abbott Diagnostics AB Sciex UK Ltd ACB

Commercial Partners Participating Company S TA N D

PA G E

12

50

21

48

27

50

8

51

Alpha Laboratories Ltd

16

51

Bayer HealthCare

23

52

Biotage AB

13

52

A.D.P. Laboratory Services Agilent Technologies Alere Ltd

Anatune Ltd

Beckman Coulter UK Ltd Bruker UK

10 32 6

18

50 51

51 52

7

53

CitySprint Healthcare

38

53

DiaSorin Ltd

40

54

Chromsystems Instruments and Chemicals Department of Health ELGA LabWater

19

30

53

53

14

54

5

54

Launch Diagnostics Ltd

35

55

Menarini Diagnostics Ltd

11

Nova Biomedical

41

Helena BioSciences Europe HemoCue Ltd

Immunodiagnostics Systems (IDS) Ltd Lynx Environmental Ltd NHS Improvement

Ortho Clinical Diagnostics

17 9 1

42

55

-

55

56

56

48

31

49

39

ScheBo Biotech UK Ltd

29

Roche Diagnostics Ltd

54

3

PerkinElmer

56

56

Sebia (UK) Ltd

24

57

Thermo Fisher Scientific

15

57

Waters Ltd

34

58

Siemens Healthcare Diagnostics TouchPoint Medical Ltd WEQAS

–

33 22

The Editor and the ACB accept no responsibility for any claims made by companies in these Abstracts.

Focus 2011 | Exhibi8on | Index

Exhibition Index

49

57 58

47

Focus 2011 | Exhibi8on | Commercial Partners

48

Commercial Partners Stand 21

Abbott Diagnostics

Put science on your side at Focus 2011

As always, Abbott Diagnostics is pleased to support the Association for Clinical Biochemistry as a commercial partner at its premier scientific meeting of the year.

Quality clinical science is at the heart of fulfilling unmet clinical needs in many disease areas and with this in mind science is once again at the heart of Abbott’s presence at Focus.

So, whether you attend our hosted parallel scientific session (Cancer – Meeting The Needs of the Patient) on Wednesday 25th May, 08.45-10.45 or drop by Stand 21 to find out about our latest scientific developments; we very much look forward to seeing you and discussing how Abbott can help you put science on your side. Further information from: Carla Deakin, Abbott Diagnostics, Abbott House, Vanwall Business Park, Maidenhead, Berkshire SL6 4XF Tel: 01628 644217 Fax: 01628 644205 e-mail: [email protected] Website: www.abbottdiagnostics.com

Stand 3

Ortho Clinical Diagnostics

VITROS® is more than technology. It’s a total solution for meeting your operational and patient care goals.

Ortho Clinical Diagnostics (OCD) develops sophisticated approaches to identifying and satisfying the differing workload requirements of UK laboratories. We can apply Lean methodologies to enhance workflow and eliminate waste from laboratory processes. Our proven technology includes the VITROS® Family of Systems, VITROS® 5600 Integrated System, VITROS 3600® Immunoassay System and VITROS 4600® Chemistry System which all link directly to the flexible range of enGen™ automation modules, that meet individual laboratories needs.

With the benefit of e-Connectivity technology we can maximise your uptime by allowing our technical team to monitor your system online through a secure, real-time, two-way connection. Our Remote Monitoring Centre identifies potential issues and dispatches engineers – often before you even know there’s a problem. The result is timely resolution that minimises unplanned downtime.

OCD will be hosting an Industry Sponsored Workshop on Tuesday 24th May at 10.45 entitled Blood Sciences Laboratory in the small or specialist hospital: is it a worthwhile approach? Further information from: Peter Clements, Ortho Clinical Diagnostics, Johnson & Johnson, 50-100 Holmers Farm Way, High Wycombe, Buckinghamshire HP12 4DP Tel: 01494 658600 Fax: 01494 658605 e-mail: [email protected] Website: www.orthoclinical.com

Roche Diagnostics Ltd

Leaders in Providing Pathology-Wide Managed Laboratory Services

Roche are delighted to be able to offer enhanced support for the ACB in 2011 with increased levels of sponsorship for the Focus scien8fic programme and local ACB mee8ngs.

At Focus 20011, Roche will be providing informa8on on the benefits that our Managed Laboratory Services and scalable product por7olio can bring to your Trust. We will provide a welcoming, relaxed atmosphere where you can find out more informa8on about the advantages of a Roche partnership, and ask any ques8ons you may have.

For further informa8on on Managed Laboratory Services and our scalable product por7olio, please visit Roche on Stand 31.

Further information from: Peter Jones, Hospital IVD, Roche Ltd, Charles Avenue, Burgess Hill, West Sussex RH15 9RY Tel: 01444 256787 e-mail: [email protected] Website: www.roche.com

Diagnostics

Siemens Healthcare Diagnostics

The Siemens Healthcare Sector is one of the world’s largest suppliers to the healthcare industry and a trendse9er in medical imaging, laboratory diagnos8cs, medical informa8on technology and hearing aids. Siemens offers its customers products and solu8ons for the en8re range of pa8ent care from a single source – from preven8on and early detec8on to diagnosis and on to treatment and a(ercare. By op8mising clinical workflows for the most common diseases, Siemens also makes healthcare faster, be9er and more cost-effec8ve. Siemens Healthcare employs some 48,000 employees worldwide and operates around the world. In fiscal year 2010 (to September 30), the Sector posted revenue of 12.4 billion euros and profit of around 750 million euros.

Further information from: Ruth Powell, Siemens Healthcare Diagnostics, Newton House, Sir William Siemens Square, Frimley, Surrey GU16 8QD Tel: 01276 696000 Fax: 01276 696680 e-mail: [email protected] Website: www.siemens.co.uk/diagnostics

Focus 2011 | Exhibi8on | Commercial Partners & Sponsor

Stand 31

49

Focus 2011 | Exhibi8on | Par8cipa8ng Companies

50

Participating Companies Stand 12

AB Sciex UK Ltd

AB Sciex is a global leader in the development of life science analytical technologies that help answer complex scientific challenges.

AB Sciex provides instrumentation, software and services that are used in a number of critical life science applications, including protein biomarker research, disease studies, drug discovery and development, and food and environmental safety.

AB Sciex is uniquely positioned to continue its global leadership in the mass spectrometry market, building on a more than 20-year history of innovation. Further information from: Cheryl Goodall, AB Sciex UK Ltd, Phoenix House, Lakeside Drive, Centre Park, Warrington, Cheshire WA1 1RX Tel: 01925 236060 Fax: 01925 236070 e-mail: [email protected] Website: www.absciex.com

Stand 27

Association for Clinical Biochemistry (ACB)

The Association for Clinical Biochemistry would like to welcome everybody to Focus 2011 in Harrogate, ‘Focus on Change’.

The Association’s stand will have a full range of Venture publications books, CDs and journals, together with a range of AACC books available at a discount. Orders may be placed for any of the publications and be sent to your work or home address, but make further savings by taking the goods away on the day and incur no P&P charges. Member’s ties and pins are also available.

Annals of Clinical Biochemistry One of the world’s foremost in its field, the Annals publishes fully refereed papers of international authorship that contribute to existing knowledge in all fields of clinical biochemistry, especially that pertaining to the understanding, diagnosis and treatment of human disease. It also publishes papers on immunology, genetics, biotechnology, haematology, computing and management where they have both biochemical and clinical relevance. The 2009 Impact Factor for Annals of Clinical Biochemistry was 1.917. If you have any questions regarding the journal, please call at the ACB stand and talk to a member of the ACB office staff.

Lab Tests Online UK (LTOL) www.labtestsonline.org.uk Lab Tests Online UK was first published in 2004. The site has grown exponentially and each year receives over 1 million visitors looking at some 4 million pages. Patients and their carers will find simple explanations and answers to their questions about lab tests whether they are from clinical biochemistry, haematology, microbiology, immunology, cytology or histopathology.

The site has been endorsed by the Department of Health, is used by NHS Choices, cited on many hospital Pathology websites and used by health policy makers. It is described as 'the single most authoritative source of information about laboratory tests on the web.

Meet the Committee Representatives Members of the ACB Executive and other committees that act on your behalf will be available on the ACB stand at various times during Focus to answer questions and provide information on any aspect of the Associations activities and your careers.

Officials from the Federation of Clinical Scientists (FCS) will be on hand each day to help you with any queries you have on agenda for change and other work-related issues.

Labs Are Vital Labs Are Vital promotes the importance and value of laboratory medicine to healthcare commissioners through a number of UK events and provides tools for laboratory professionals to promote their own service.

The initiative is supported by the ACB, RCPath, IBMS, ACP and BIVDA, together with Abbott Diagnostics (www.labsarevital.co.uk). Further information from: Nic Law, ACB Administrative Office, 130-132 Tooley Street, London SE1 2TU Tel: 020 7403 8001 Fax: 020 7403 8006 e-mail: [email protected] Website: www.acb.org.uk

Stand 10

A.D.P. Laboratory Services

Bringing Innovation to Point of Care Testing and Drugs of Abuse Analysis, with fully barcoded Rapid Tests, facilitating traceability and patient reporting.

Introducing Cliniqa Liquid QC Material, with excellent shelf life and up to 3 months open vial

Further information from: Greg Simpson/David Moloney, A.D.P. Laboratory Service, One Meadowbank Road, Trooperslane Industrial Estate, Carrickfergus, Unit 14, Bullford Business Campus, Kilcoole, Co. Wicklow Tel: 02893 366929 / 00 353 12812304 Fax: 02893 366929 / 00353 12812307 e-mail: [email protected] Website: www.advancediagnostics.ie

Stand 8

Agilent Technologies

For more than 70 years, Agilent Technologies has been the world’s premier measurement company. Our singular focus on measurement helps scientists and engineers address their toughest challenges with precision and confidence. With the help of our products and services, they are better able to deliver the breakthroughs that make a measurable difference in the world. Key products include: Liquid and Gas Chromatography, Mass spectrometry, Microfluidics, Oligo library solutions and microarrays, Reagents chemistry, LC and GC Columns, Software and Informatics, Lab Automation, Nuclear magnetic resonance, Vacuum technology, X-ray, atomic and molecular spectroscopy.

With the help of our products and services, scientists and engineers are better able to deliver the breakthroughs that make a measurable difference in the world. Researchers use Agilent tools to uncover the possible causes of cancer, heart disease, autism and a multitude of other diseases – and to develop drugs that help treat them. Providing measurement solutions for biochemistry, the pharmaceutical industry, and the academic research community is the fastest growing part of our business. Further information from: Kylie Wilson, Agilent Technologies, 5500 Lakeside, Cheadle Royal Business Park, Stockport SK8 3GR Tel: 0845 712 5292 Fax: 0845 600 835 e-mail: [email protected] Website: www.agilent.com

Stand 32

Alere Ltd

Alere™ is one of the largest diagnostic companies in the world and employs over 850 people in the UK at multiple locations.

Alere products and solutions are changing how healthcare is delivered—extending diagnosis and

health management from the lab, GP practice and hospital into people’s homes.

Alere actively integrates diagnostic tools with education and health management solutions, making it easier than ever to personalize care. We’re connecting patients to information. Information to diagnostic results. And diagnostic results to healthcare providers, so they have the information needed to make the best decisions. Want to find out more? Visit www.alere.co.uk

Further information from: Jackie Dootson/Clare Mannion, Alere Ltd, Pepper Road, Hazel Grove, Stockport SK7 5BW Tel: 0161 483 5884 Fax: 0161 483 5778 e-mail: [email protected] Website: www.alere.co.uk

Stand 16

Alpha Laboratories Ltd

Laboratories are facing the most stringent efficiency drive encountered in recent times. One way to provide your hospital with a means to decrease costs whilst enhancing the patient’s clinical outcome is by the use of new Biomarkers.

Alpha Laboratories Ltd has a proven track record in working with laboratories and clinicians in order to provide these benefits by the use of Faecal Calprotectin. This assay enables the end user to easily and confidently distinguish between IBS and IBD thereby reducing the number of colonoscopies required in the UK.

We have recently launched two more novel Biomarkers, Hyaluronic Acid and Neutrophil Gelatinase-associated Lipocalin (NGAL) assays which can be analysed on routine clinical chemistry analysers. This year Alpha Laboratories will sponsor a workshop entitled “Focus on Acute Kidney Injury (AKI) with NGAL & Liver Fibrosis with Hyaluronic Acid” which will feature two keynote speakers. Please visit us at stand 16 to discuss our products.

Focus 2011 | Exhibi8on | Par8cipa8ng Companies

stability, covering, general chemistry, proteins, cardiac, HbA1C and urinalysis.

Further information from: Alpha Laboratories Ltd, 40 Parham Drive, Eastleigh, Hampshire SO50 4NU Tel: 023 8048 3000 Fax: 023 8064 3701 e-mail: [email protected] Website: www.alphalabs.co.uk

Stand 6

Anatune Ltd

Anatune is a leading chromatography solution provider in the UK. The company has something to

51

Focus 2011 | Exhibi8on | Par8cipa8ng Companies

52

offer all laboratories that use chromatography, but specialises in offering solutions, products and services to clinical, environmental, pharmaceutical, food, flavour and fragrance laboratories. Most major businesses in these sectors are regular customers. Founded in 1996, the vision was to create a company which would be more than a supplier of Chromatography equipment. Today, its philosophy is that real customer value comes from combining industry, scientific and application knowledge with an emphasis on solving problems and creating efficiency and effectiveness. The focus is on data quality, robustness, reliability, simplicity and speed, all whilst driving down cost per sample.

As a supplier of equipment from one of the world's best and most trusted chromatography manufacturers, Anatune is uniquely placed to combine the best technologies available to solve problems. Further information from: Susan Gilbert, Anatune Ltd, Broadway House, 149-151 St Neots Road, Hardwick, Cambridgeshire CB23 7QJ Tel: 01954 212909 Fax: 01954 212908 e-mail: [email protected] Website: www.anatune.co.uk

Stand 23

Bayer HealthCare

Bayer HealthCare is one of the world’s leading, innovative companies in the healthcare and medical products industry. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover and manufacture products that will improve human and animal health worldwide. Bayer Healthcare has a global workforce of 53,400 employees and is represented in more than 100 countries.

The pharmaceutical division of Bayer HealthCare focuses its research and business activities on the following areas: Diagnostic Imaging, General Medicine, Haematology & Neurology, Oncology and Women’s Healthcare. Using innovative ideas, Bayer aims to make a contribution to medical progress and strives to improve the quality of patients’ lives.

Our Men’s Health portfolio features products for testosterone therapy and erectile dysfunction.

Further information from: Bayer HealthCare, Bayer House, Strawberry Hill, Newbury, Berkshire RG14 1JA Tel: 01635 563000 Fax: 01635 563693 e-mail: [email protected] Website: www.bayer.co.uk

Stand 18

Beckman Coulter UK Ltd

Beckman Coulter is one of the leading providers of in vitro diagnostic systems to hospital laboratories throughout the world. We are uniquely positioned as a company with both research and diagnostic divisions to lead the way in biomedical testing.

Our focus in Harrogate will be to share with you some of our innovative science and demonstrate how this innovation can improve the patient experience and reduce the cost of healthcare. We look forward to seeing you at Focus 2011. Further information from: Leanne Annereau, Beckman Coulter, Oakley Court, Kingsmead Business Park, London Road, High Wycombe HP11 1JU Tel: 01494 441181 Fax: 01494 429294 e-mail: [email protected] Website: www.beckmancoulter.com

Stand 13

Biotage AB

Biotage is a global leader in life science technology. With a broad scope of tools for synthesis, work-up, purifica8on, evapora8on and analysis, the company provides solu8ons and exper8se in the areas of analy8cal and medicinal chemistry.

Biotage manufactures a range of sample prepara8on tools for bioanaly8cal, clinical, environmental, food and forensic applica8ons. With a variety of sorbent chemistries, Biotage products deliver cleaner extracts with higher analyte recovery for precise analysis.

ISOLUTE SLE+ provides quicker, cleaner and cheaper analysis with a simple “load, wait and elute” methodology.

Addi8onally, EVOLUTE polymeric sorbents provide a highly effec8ve solu8on to the problems of ion suppression and matrix effects from dirty extracts. These high performance sorbents allow scien8sts to use a generic approach for a wide range of compounds, thus reducing method development 8me and allowing for clean extracts. Further information from: Ma9 Wheeler, Biotage AB, Kungsgatan 76, SE-753 18 Uppsala, Sweden Tel: + 46 18 56 59 00 Fax: + 46 18 59 19 22 e-mail: [email protected] Website: www.biotage.com

Bruker UK

Bruker is a leading provider of high performance analy8cal systems whose innova8ve and easy to use product families encompass a variety of Mass Spectrometers and Gas Chromatography instruments. Bruker u8lizes LC/GC/MS based and other MS instruments (ESI-TOFs, Ion Traps, FTMS, MALDI-TOFs, single and triple quadrupole GCMS, and ICP-MS) to provide outstanding results for a wide range of small molecule and protein analysis applica8ons. Delivering premium value, and backed by decades of Applica8on and Technical Support exper8se, Bruker systems enable scien8stsd working in Applied Analy8cal, Life Science, and the Clinical Research laboratories to answer even the most challenging analy8cal ques8ons. Further information from: James Hillis, Bruker UK, Bawner Lane, Coventry CU4 9GH Tel: 0781 855 0349 Fax: 0247 646 5317 e-mail: [email protected] Website: www.bruker.com

Stand 19

Chromsystems Instruments and Chemicals

Chromsystems has revolutionised HPLC analysis for routine diagnostics and now pioneers in developing reagent kits, calibrators and controls for tandem mass spectrometry. The company continues to set standards for high technology solutions for diagnostic laboratories. Optimised work flows yield quick and reliable results.

Certified products facilitate compliance with regulatory rules. The Chromsystems product range covers a broad spectrum of diagnostic analyses such as therapeutic drug monitoring, vitamin profiling, newborn screening, biogenic amines, vitamin D and more. All analyses are completely validated and ready to use. Calibrators and quality controls can also be used for HPLC and mass spectrometry analyses independent from Chromsystems kits. An extensive service network guarantees global availability and service. Regular training courses add to customer success. Several products are FDA-listed. For more information please visit our website www.chromsystems.de.

Further information from: Chromsystems Instruments & Chemicals GmbH, Heimburgstrasse 3, 81243 Munich, Germany Tel: +49 89 189 30 300 Fax: +49 89 189 30 399 e-mail: [email protected] Website: www.chromsystems.de

Stand 38

CitySprint Healthcare

CitySprint Healthcare comprises a range of solutions which have been designed to support the healthcare sector as a whole.

The specific services have been developed with extensive knowledge and experience of the medical and pharmaceutical sectors, and provide efficient, effective transportation solutions for example for pathology, organ transplants, hospital based courier services, logistic solutions for pharmacies and patient home deliveries. As a leading provider of such solutions, CitySprint is ideally placed to provide total outsourced fleet solutions or flexible ad-hoc support.

CitySprint Healthcare can provide up-to-date advice on the classification of biological and hazardous material. Our dedicated team can help with all aspects of your shipping needs from planning the most efficient routes and delivering bespoke packing for temperature controlled solutions.

Our network of 31 wholly owned Service Centres across the UK ensures that we can provide a secure and rapid response service 24 x 7 x 365.

Further information from: Andrew Turner, CitySprint Healthcare, Ground Floor RedCentral, 60 High Street, Redhill, Surrey RH1 1SH Tel: 0870 873 2219 e-mail: [email protected] (for organisation queries [email protected]) Website: www.citysprint.co.uk/healthcare

Stand 30

Department of Health

Focus 2011 | Exhibi8on | Par8cipa8ng Companies

Stand 7

The Department of Health (DH) exists to improve the health and wellbeing of people in England. The DH Pathology Programme is working to support the NHS in ensuring that pathology services are fit for the future. The vision is for high quality and cost-effective NHS pathology services that are commissioned according to user and patient need, are flexible enough to utilise innovative technologies and play a crucial role in improving patient outcomes.

Visit our stand to see the latest from the Quality and Productivity Challenge (QIPP), Modernising Scientific Careers and NHS Improvement. Further information from: Daniel Gosling, Pathology Programme, Department of Health, Wellington House, 133-155 Waterloo Road, London SE1 8UG Tel: 020 7972 4329 e-mail: [email protected] Website: www.dh.gov.uk

53

Focus 2011 | Exhibi8on | Par8cipa8ng Companies

54

Stand 40

DiaSorin Ltd

Over the last 40 years DiaSorin has built the reputation of being a Diagnostic Specialist. We differentiate ourselves from the competition by listening to our customers’ needs and developing products that meet their requirements. We also pride ourselves on our customer focus and professionalism.

The LIAISON® analyser offers one of the largest immunoassay menus on a single platform, including the unique Direct Renin and 1-84 PTH assays as well as the market leading Vitamin D TOTAL assay. 2011 is a landmark year for DiaSorin, not only will we place our 4000 LIAISON® system worldwide we will launch the LIAISON XL® our new, high throughput, random access analyser to meet the demands of the medium and large sized laboratories. To learn more about our product offerings and the LIAISON XL® analyser please visit us on Stand 40.

From all of the DiaSorin team, we wish you an enjoyable and informative congress. Further information from: Darren Tomlinson, DiaSorin Ltd, 1st Floor Richmond House, Oldbury, Bracknell RG12 8TQ Tel: 01344 401 430 Fax: 01344 401 431 e-mail: [email protected] Website: www.diasorin.com

Stand 14

ELGA LabWater

ELGA LabWater MEDICA systems, designed and built in the UK, are perfectly suited to feed the latest clinical analysers. Utilising a unique combination of technologies in single box systems to give CLSI type 1 water quality.

• MEDICA systems deliver up to 400 litres of water per hour, through duplexed analyser feed loops, ensuring dependability through no single point of failure. • Bacterial control, vital for Immunoassays is maintained through recirculation of pure water through RO, DI, UV and Ultra Filtration technologies. • ELGA Aquaservice Managed Service Contracts provide guaranteed running costs, giving true Risk shift from public to private sector. We have the reputation and sustainable solutions to reduce water usage, energy bills and CO2 associated with heating and pumping. Our EcoBin service provides a simple and safe solution for the

collection, recycling and disposal of non hazardous wastes including consumables, installation waste materials and analyser reagent cassettes/vessels.

Further information from: John Page, Elga LabWater, Marlow International, Parkway, Marlow, Buckinghamshire SL7 1YL Tel: 01628 897000 Fax: 01628 897001 e-mail: [email protected] Website: www.elgaprocesswater.co.uk

Stand 17

Helena BioSciences Europe

We design, manufacture and market the most innova8ve diagnos8c and biomedical products for the advancement of healthcare and medical science. Specialising in clinical electrophoresis and haemostasis, we con8nue a long and established tradi8on of progress and reliability, providing clinicians and scien8sts with a comprehensive por7olio of world-class instrumenta8on, so(ware and assays, encompassing manual and automated diagnos8c systems, and rou8ne and specialist tes8ng solu8ons.

V8: Automated Capillary Electrophoresis System Helena BioSciences Europe now supply the most automated capillary electrophoresis system, providing biomedical scien8sts with an intelligent, high-throughput and mul8-assay solu8on integra8ng capillary and gel electrophoresis.

Haemostasis reagents: reliable and flexible Manufacturing a full panel of haemostasis reagents, we supply tailored solu8ons for an extensive range of leading coagula8on and haematology analysers.

Superior Performance D-dimer Helena BioSciences manufacture the highest quality D-dimer reagents in flexible kit formats, compa8ble with market-leading coagulometers and clinical chemistry analysers.

In addi8on to world-class diagnos8c systems, we provide the most compe88ve prices on molecular biology and 8ssue culture products.

Further information from: Adam Stephenson, Helena BioSciences Europe, Queensway South, Team Valley Trading Estate, Gateshead, Tyne and Wear NE11 0SD Tel: 0191 482 8440 Fax: 0191 482 8442 e-mail: [email protected] Website: www.helena-biosciences.com

Stand 5

HemoCue Ltd

HemoCue focuses on the change for Diabetes Point of Care. Visitors to the HemoCue stand will be able to see and try for themselves the company’s full

Extensively used throughout the world for screening and diagnosing multiple conditions, HemoCue tests have been demonstrated to guarantee laboratory precision and accuracy in all point of care situations. With their advanced data management and connectivity capabilities, the latest DM analysers not only communicate with the laboratory, but can also download patient results directly to patient information management systems. Dedicated to point of care analysis, HemoCue’s solutions to diagnostic situations provide the laboratory accurate answers for all healthcare professionals. Further information from: Anneliese Holland, HemoCue Ltd, Viking Court, Princess Road, Dronfield, Derbyshire S18 2LX Tel: 0844 88 00 996 e-mail: [email protected] Website: www.hemocue.com

Stand 9

Immunodiagnostics Systems (IDS) Ltd

IDS is dedicated to the development and provision of innovative immunoassays worldwide. Renowned for vitamin D Tests; 25-OHD, and 1,25 (OH)2 vitamin D, IDS provides a comprehensive range of speciality immunoassays for diagnostic and research use. IDS will be exhibiting the IDS-iSYS automated immunoassay system for bone, growth, cartilage and hypertension assays. The IDS-iSYS automated immunoassay system is well equipped to consolidate your “send-away” testing and improve turnaround time. Please come and talk to us about our automated, co-specific 25-OH vitamin D assay, or about how the growth assays from IDS comply with recent guidelines from the Consensus Workshop at the Growth Hormone Research Society Meeting on hGH and IGF-I Assays (Keswick Hall, Virginia, USA). We would also be happy to discuss our complete range of automated bone markers for resorption, formation and bone turnover.

An IDS industry workshop will take place in the Queen’s Suite on Wednesday 25th at 10.55 on “Clinical Application of Bone Markers”, by Prof Erik Fink Eriksen MD, DMSc, University Hospital of Oslo.

Further information from: James Crofts, IDS Ltd, 10 Didcot Way, Boldon Business Park, Boldon, Tyne & Wear NE35 9PD Tel: 0191 519 660 Fax: 0191 519 0760 e-mail: [email protected] Website: www.idsplc.com

Stand 35

Launch Diagnostics Ltd

Launch Diagnos8cs are pleased to a9end Focus 2011 and hope that you will join us on our stand as we launch two new ranges;

Diazyme Vit D, a fully automated Elisa assay on the DS2 pla7orm. Detec8ng D2 and D3, it provides excellent performance and correla8on with the GC-MS reference method. Results can be obtained for 160 samples within three hours. The new ARKRAY ADAMS HA-8180 HbA1c. The HA-8180 is a fast HbA1c analyser, featuring full automa8on and dual repor8ng. MEQNET link so(ware allows new and exis8ng ARKARY instruments to be interfaced with LIMS systems.

Further information from: Pauline Boyle, Launch Diagnos8cs Ltd, Ash House, New Ash Green, Longfield, Kent DA3 8JD Tel: 01474 0874426 Fax: 01474 872388 e-mail: [email protected] Website: launchdiagnos8cs.com

Stand 11

Menarini Diagnostics Ltd

Focus 2011 | Exhibi8on | Par8cipa8ng Companies

range of analysers and be able to test their new platform of solutions for diabetes. HemoCue’s range of analysers provide the key parameter results needed for top diabetes diagnostics and care.

Menarini Diagnostics are celebrating the launch of our latest analyser for HbA1c and Haemoglobinopathies the HB9210 and would like you to come and join us at Stand 11 for a celebratory drink. The analyser is the latest chapter in our 20 year history of supporting HbA1c and Haemoglobinopathy diagnosis in the UK and Europe. We will have information on the new analyser as well as our full range of diagnostic systems. Our staff will be pleased to answer your questions and discuss your laboratory’s requirements. We look forward to seeing you there! Further information from: Brendan O’Dwyer, Menarini Diagnostics Ltd, Wharfedale Road, Wokingham, Berkshire RG41 5RA Tel: 0118 944 4100 Fax: 0118 944 4111 e-mail: [email protected] Website: www.menarinidiag.co.uk

55

Focus 2011 | Exhibi8on | Par8cipa8ng Companies

56

Stand 42

NHS Improvement

Working with over 240 sites across England, NHS Improvement works with NHS organisations and clinical networks to help transform, deliver and build sustainable improvements across the entire pathway of care in cancer, diagnostics, heart, lung, stroke and audiology services. With ten years practical improvement experience, NHS Improvement aims to develop sustainable effective pathways and systems, share improvement resources and learning, increase impact and ensure value for money to improve the efficiency and quality of NHS services.

With a focus on quality, productivity and innovation, NHS Improvement works closely with the NHS Medical board and Department of Health with all work aligned to national priorities and supporting delivery of key national strategies. With a continued focus on the delivery of quality improvements based on the latest evidence-based practice and a robust monitoring of performance, the work of NHS Improvement makes a significant practical difference to services along the patient pathway and is clinically led and patient focused to achieve the best outcomes. Further information from: Iain Fletcher, Communications Director, NHS Improvement, 3rd Floor, St John’s House, East Street, Leicester LE1 6NB Tel: 0116 222 5113 Fax: 0116 222 5101 e-mail: [email protected] Website: www.improvement.nhs.uk

Stand 41

Nova Biomedical

The design and manufacture of biosensors for use in Point of Care Testing devices has been the speciality of Nova Biomedical for over 30 years. The Nova StatStrip® Glucose system provides laboratory accuracy in a POC setting. StatStrip® patented multi-well technology requires no calibration codes, has no known interferences including haematocrit, maltose, galactose, xylose, ascorbate etc and is easy to use. StatStrip® provides QC lock-out, bar-coded ID, and full connectivity. Other StatStrip® meters include lactate for sepsis management and glucose with ketones offering the most accurate measurement of whole blood ketones for detection and management of DKA as per recent JBDS and BSPED guidelines. StatSensor-i® gives POC creatinine/eGFR results in 30 seconds

offering Radiologists, Oncologists, ICU and A&E an accurate, reliable assessment of renal function. Stat Profile® pHOx and pHOx Ultra uniquely offer a comprehensive critical care test menu including: blood gas, electrolyte, metabolite and co-oximetry measurements; uniquely urea, creatinine, ionised magnesium and total bilirubin are available on the Ultra. Further information from: Linda McGough, Nova Biomedical, C3-5 Evans Business Centre, Deeside Industrial Park, Deeside, Flintshire CH5 2JZ Tel: 01244 287087 Fax: 01244 287080 e-mail: [email protected] Website: www.novabiomedical.com

Stand 39

PerkinElmer

PerkinElmer is a global company focused on improving the health and safety of people and their environment. From earlier medical insights and more effective therapies to cleaner water and safer homes, PerkinElmer touches the lives of millions of people around the world every day.

As the global leader in newborn screening and prenatal risk assessment, PerkinElmer has pioneered the application of tandem mass spectrometry in newborn screening. This technology enables programs to screen for several tens of disorders using a single blood sample.

Now, for clinical laboratories that wish to put the power of mass spectrometry to work, the company’s new generation clinical MS/MS kits are designed to meet present and future assay needs. The MS/MS Steroids kit supports measurement of 10 steroid analytes in the same aliquot, while the new MS/MS Vitamin D kit provides enhanced detection for 25-OH-vitamin D /D3. Both assays are suitable for use with most MSMS instruments. Further information from: Nick Withers, PerkinElmer, Chalfont Road, Seer Green, Beaconsfield HP9 2FX Tel: 07876 394203 e-mail: [email protected] Website: www.perkinelmer.co.uk

Stand 29

ScheBo Biotech UK Ltd

ScheBo Biotech is proud of the scientific and clinical evidence supporting our products. Our monoclonal antibody ScheBo Pancreatic Elastase-1 Stool Test ('faecal elastase') is widely regarded as the non-invasive “test of choice” for pancreatic exocrine function.

Faecal lactoferrin is a dependable, economical and highly practical biomarker of gastrointestinal inflammation. A quantitative ELISA (IBD-SCAN) and a 10-minute qualitative rapid test (IBD EZ VUE) are available.

Ask us about the price of the tests and the evidence for their use to differentiate Irritable Bowel Syndrome (IBS) from active Inflammatory Bowel Disease (IBD), to monitor therapy response and to detect disease “flares” in IBD. Further information from: Ivor Smith, ScheBo Biotech UK Ltd, POBox 6359, Basingstoke RG22 4WE Tel: 01256 477259 Fax: 01256-327889 e-mail: [email protected] Website: www.schebo.co.uk

Stand 24

Sebia (UK) Ltd

Sebia is a world leading manufacturer of automated electrophoresis systems for routine and specialist biochemistry, haematology and immunology testing.

Established in 1967, Sebia continues to respond to evolving customer needs through investment in new product research and development. A key highlight at Focus is Capillarys 2 Flex Piercing, featuring cap piercing for sampling directly from primary tubes and a NEQAS listed method for haemoglobinopathy detection. From summer 2011, Flex Piercing will also be available on Minicap, making it ideal for serum analysis for protein electrophoresis, immunotyping and CDT in smaller and multidisciplinary laboratories. Also on stand, Hydrasys 2 automatically carries out all phases of electrophoresis testing. Working in conjunction with Hydrasys 2 and data acquisition software Phoresis, Sebia’s new autosampler, ASSIST, provides automation and positive sample identification while ensuring standardisation of all pre-analytical steps. Sebia additionally provides scientific support and professional training through external seminars, on-site training and electrophoresis workshops.

Further information from: Chris Plows, Sebia (UK) Ltd, River Court, The Meadows Business Park, Station Approach, Blackwater, Camberley, Surrey GU17 9AB Tel: 01276 600636 Fax: 01276 38827 e-mail: [email protected] Website: www.sebia.co.uk

Stand 15

Thermo Fisher Scientific

Thermo Fisher Scientific is a world leader in serving science, enabling you to make the world healthier, cleaner and safer. With annual sales of more than $10 billion and 30,000 staff, we serve over 350,000 customers worldwide within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industrial process control settings.

With two premier brands, Thermo Scientific and Fisher Scientific, we help solve analytical challenges from routine testing to complex research and discovery.

Thermo Scientific offers customers a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables and reagents to enable integrated laboratory workflow solutions. Further information from: Paul Humphrey, Thermo Fisher Scientific, Boundary Way, Hemel Hempstead HP2 7GE Tel: 01442 233 555 Fax: 01442 233 667 e-mail: [email protected] Website: www.thermoscientific.com

Focus 2011 | Exhibi8on | Par8cipa8ng Companies

The ScheBo M2-PK Stool Test is a different approach to colorectal cancer screening. Patients with a raised faecal concentration of dimeric M2-PK should undergo further investigation (e.g. colonoscopy). This non-invasive test delivers high sensitivity and specificity from a single small faecal sample. The EDTA-plasma test assists with monitoring for therapeutic efficacy, patient follow-up for relapse/metastasis, and diagnosis in many different cancers.

Stand 33

TouchPoint Medical Ltd

TouchPoint is a new company focused on Point of Care in the UK. The rapid shi( of technology from conven8onal instruments used in major hospitals to now tes8ng at the point of pa8ent care; we are at the forefront, and have developed an integrated POCT system in line with this trend in diagnos8cs. Our aim is to bring new, validated and compelling analy8cal technologies to laboratory scien8sts and clinicians focused on providing the best point of care op8ons for their pa8ents. Our technologies have been developed to pioneer a new paradigm in POCT. For example; our new i-CHROMA system delivers results in 3-15 minutes a(er taking the blood sample from the pa8ents’ finger8p right in your laboratory or office.

57

Focus 2011 | Exhibi8on | Par8cipa8ng Companies

58

Our diagnos8c system is op8mised for screening major “lifestyle” related diseases including, but not limited to, cardiac diseases, cancers and diabetes.

Further information from: John Bolodeoku, TouchPoint Medical, Siena Court, Broadway, Maidenhead, Berkshire SL6 1NJ Tel: 01628 509014 Mobile: 07765 401135 Fax: 01628 509100 e-mail: [email protected] Website: www.touchpoint-medical.com

Stand 34

Waters Ltd

Waters Corporation has 50 years history developing innovative HPLC, mass spectrometry, software, chemistry and support services. Waters can now provide clinical research laboratories with complete solutions that improve accuracy and precision of those assays and increase productivity.

The use of LC/MS/MS in clinical research laboratories is rapidly expanding and now includes applications such as steroid analysis, homocysteine, methylmalonic acid and Vitamin D, among others. In these applications, Waters MassTrak Systems offer improved accuracy and precision. In addition, the methods are simpler, faster and require less sample pre-treatment than the traditional LC or immunoassay methods. Waters clinical business organisation is fully dedicated to developing groundbreaking solutions for diagnostic laboratories.

To find out more, visit us on stand 34.

Further information from: Kim Hobbs, Waters, 730-740 Centennial Court, Centennial Park, Elstree, Hertfordshire WD24 7LS Tel: 0208 238 6100 Fax: 0208 238 6170 e-mail: [email protected] Website: www.waters.com

Stand 22

WEQAS

WEQAS is one of the leading External Quality Assessment (EQA) providers with programmes developed to keep abreast of technological advancements and speciality areas. Our Schemes are underpinned by commutable samples, reference methods, informa8ve reports, and a team of experienced scien8sts and point of care co-ordinators. WEQAS POCT provides EQA samples to over 80% of NHS hospitals, PCTs and pharmacies in the UK. With the increased volume and novel applica8ons in Point of Care Diagnos8cs our vast experience in this sector can help you assure their safe delivery.

Focus on Change – The Na8onal Quality Assurance Advisory Panel (NQAAP) is implemen8ng a new strategy on laboratory performance to ensure that the quality criteria reflects clinical use. WEQAS has taken a proac8ve role in the support and implementa8on of the MAPS project (Minimum Analy8cal Performance Standards) and has modified our reports to reflect this ini8a8ve. Visit our stand to find out more about how this affects you.

Further information from: Annette Thomas, WEQAS Quality Laboratory, Unit 6 Parc Tyglas, Cardiff Business Park, Llanishen, Cardiff CF14 5DU Tel: 02920 314750 Fax: 02920 314760 e-mail: offi[email protected] Website: www.weqas.com

Focus 2011 | Notes

Notes

59

Focus 2011 | Notes 60

Notes

Our thanks to . . . The Focus 2011 Committee would like to thank all companies who have sponsored the meeting. The Commercial Partners for this meeting are:

Abbott Diagnostics

Ortho Clinical Diagnostics

Roche Diagnostics Ltd

Siemens

Diagnostics